Hologic (HOLX)

Company ID: 238 | CIK: 0000859737
10-Q view:
No 10-Q YTD data
No 10-Q 3M data
No 10-K data
No 10-K data
No 10-Q YTD data
No 10-Q 3M data
No 10-K data
No 10-K data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
Segments are charted by their disclosed metrics (revenue, segment profit, etc.). Each line is a single segment. Reconciliation/corporate items are excluded. Major customers are shown as a percentage of revenue. Operational KPIs are grouped by metric concept; sub-metrics appear as separate lines.

Geographic Segments

No 10-Q data
No 10-Q data

Business Unit / Product Segments

Major Customers (% of Revenue)

Operational KPIs

Digital imaging backlog (backlog)

No 10-Q data

Manufacturing capacity (capacity)

No 10-Q data

Common Stockholders (customers)

No 10-Q data

Workforce reduction (headcount)

Digital Imaging Backlog (order_book)

No 10-Q data

ACCLAIM share of DXA sales (other)

No 10-Q data

ACCLAIM share of product sales (other)

No 10-Q data

Adiana contingent consideration accrued (other)

No 10-K data

Adjusted EPS (STIP) (other)

No 10-Q data

Adjusted free cash flow (other)

No 10-Q data

Adjusted return on invested capital (other)

No 10-Q data

Adjusted revenue (STIP) (other)

No 10-Q data

Allowance for doubtful accounts (other)

No 10-K data

Asia sales share (other)

No 10-Q data

BioZorb litigation plaintiffs (other)

No 10-K data

Bone densitometry reimbursement rate (other)

No 10-K data

Buyback authorization remaining (other)

No 10-K data

CEO-to-median pay ratio (other)

No 10-Q data

COVID-19 assay revenue (other)

No 10-K data

COVID-19 assay sales (other)

No 10-K data

COVID-19 assay share of product revenue (other)

No 10-K data

Capital equipment awaiting DOD approval (other)

No 10-K data

Capital expenditures (other)

No 10-K data

Cash and cash equivalents (other)

No 10-K data

Cash and short-term investments (other)

No 10-K data

Common Shares Outstanding (other)

No 10-Q data

Common Stock Outstanding (other)

No 10-Q data

Common shares outstanding (other)

No 10-K data

Common shares repurchased (other)

No 10-K data

Contingent revenue not recognized (other)

No 10-K data

Convertible notes fair value (other)

No 10-K data

Cost of product sales ratio (other)

No 10-K data

Cost of service ratio (other)

No 10-K data

DXA reimbursement rate (other)

No 10-K data

DXA test reimbursement rate (other)

No 10-K data

DXA unit sales change (other)

No 10-K data

Days Sales Outstanding (other)

No 10-K data

Days sales outstanding (other)

No 10-K data

Deferred revenue released (other)

No 10-K data

Delphi Systems Installed (other)

No 10-Q data

Diagnostic revenue mix (other)

No 10-K data

Direct sales and service force (other)

No 10-Q data

Direct sales personnel (other)

No 10-Q data

Effective tax rate (other)

No 10-K data

Enterprise software implementation spend (other)

No 10-K data

Europe sales share (other)

No 10-Q data

Export product sales mix (other)

No 10-K data

Export sales (other)

No 10-K data

Export sales from US (other)

No 10-K data

Export sales mix (other)

No 10-K data

Export sales percentage (other)

No 10-K data

Export sales to unaffiliated customers (other)

No 10-K data

Export share of product sales (other)

No 10-K data

Facility renovation progress (other)

No 10-K data

Fee-per-scan installed units (other)

No 10-K data

Fee-per-scan units installed (other)

No 10-K data

Field service personnel (other)

No 10-Q data

Foreign sales mix (other)

No 10-Q data

Foreign sales share (other)

No 10-Q data

Foreign share of product sales (other)

No 10-Q data

Forward FX contract notional (other)

No 10-K data

Forward foreign currency contract notional (other)

No 10-K data

G&A expense ratio (other)

No 10-K data

General and administrative ratio (other)

No 10-K data

Geographic product sales mix (other)

No 10-K data

Geographic revenue mix (other)

No 10-K data

Gestiva deferred gain (other)

No 10-K data

Grifols royalty revenue (other)

No 10-K data

Gross margin (other)

No 10-K data

Holders of record (other)

No 10-Q data

IPR&D projects (other)

No 10-K data

IPR&D projects in process (other)

No 10-K data

IPR&D projects remaining (other)

No 10-K data

In-process R&D projects (other)

No 10-K data

Installed base of equipment (other)

No 10-Q data

Installed base of mammography systems (other)

No 10-Q data

Interest rate cap notional hedged (other)

No 10-K data

Leasing company sales share (other)

No 10-K data

Leasing company share of product sales (other)

No 10-K data

Long-term accounts receivable (other)

No 10-K data

M-IV Systems Sold (other)

No 10-Q data

Mammography Installed Base (other)

No 10-Q data

Mammography Systems Sold (other)

No 10-Q data

Mammography installed base (other)

No 10-Q data

Number Of Reportable Segments (other)

Number of Reportable Segments (other)

Operating expense ratio (other)

No 10-K data

Other international sales share (other)

No 10-Q data

Panther Instruments Installed (other)

No 10-K data

Panther instruments installed (other)

No 10-K data

Patent Applications (other)

No 10-Q data

Patent Applications Pending (other)

No 10-Q data

Patent applications (other)

No 10-Q data

Patent applications pending (other)

Patents (other)

No 10-Q data

Patents Held (other)

No 10-Q data

Patents Owned (other)

No 10-Q data

Patents licensed (other)

No 10-K data

Patents obtained (other)

Patents owned (other)

No 10-Q data

Performance stock units granted (other)

No 10-K data

Primary care revenue mix (other)

Product gross margin (other)

No 10-K data

Product sales by geography (other)

Product sales geographic mix (other)

No 10-K data

Product warranty reserve (other)

No 10-K data

QDR Systems Installed (other)

No 10-Q data

QDR-1000plus sales mix (other)

No 10-K data

R&D expense ratio (other)

No 10-K data

Relative total shareholder return (other)

No 10-Q data

Repurchase authorization remaining (other)

No 10-K data

Research and development ratio (other)

No 10-K data

Restricted stock units granted (other)

No 10-K data

Restricted stock units outstanding (other)

No 10-K data

Restructuring accrual (other)

No 10-K data

Revenue mix by geography (other)

No 10-K data

Revenue recognized from contract liabilities (other)

No 10-K data

SARS-CoV-2 assay revenue (other)

No 10-K data

SARS-CoV-2 assay revenue mix (other)

No 10-K data

SARS-CoV-2 assay revenue share (other)

No 10-K data

STIP funding level (other)

No 10-Q data

Sahara Systems Installed (other)

No 10-Q data

Say-on-pay approval (other)

No 10-Q data

Segment operating margin (other)

No 10-K data

Selling and marketing ratio (other)

No 10-K data

Service gross margin (other)

No 10-K data

Share repurchase authorization remaining (other)

No 10-K data

Shares outstanding (other)

Shares repurchased (other)

No 10-K data

Stock options granted (other)

No 10-K data

Stock options outstanding (other)

No 10-K data

Stock units outstanding (other)

No 10-K data

Strategic Alliance installed units (other)

No 10-K data

Strategic Alliance units installed (other)

No 10-K data

Systems awaiting remarketing (other)

Total debt outstanding (other)

No 10-K data

Total revenue growth (other)

No 10-K data

U.S. patents owned (other)

No 10-Q data

US product sales growth (other)

No 10-K data

US sales share (other)

No 10-Q data

United States product sales growth (other)

No 10-K data

Unrecognized stock compensation (other)

No 10-K data

Unvested RSUs (other)

No 10-K data

Unvested equity awards (other)

No 10-K data

Unvested market stock units (other)

No 10-K data

Unvested performance stock units (other)

No 10-K data

Unvested restricted stock units (other)

No 10-K data

Warranty accrual (other)

No 10-K data

Warranty accruals (other)

No 10-K data

Warranty reserve (other)

No 10-K data

Warranty reserve balance (other)

No 10-K data

Weighted average interest rate (other)

No 10-K data

Weighted average lease discount rate (other)

No 10-K data

Weighted average remaining lease term (other)

No 10-K data

Workforce reduction (other)

No 10-K data

Working capital (other)

No 10-K data

Revenue, Remaining Performance Obligation, Amount (rpo)

Facility square footage (square_footage)

Cumulative QDR systems sold (units_shipped)

Human capital disclosures. Workforce totals and demographics are point-in-time. Flow metrics use the year-to-date period for 10-Q and full year for 10-K. Workforce actions (RIFs, restructurings, acquisition-related changes) are listed in the table at the bottom.

Workforce Totals

No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data

Demographics

No 10-Q data
No 10-Q data
No 10-Q data

Workforce Breakdowns

No 10-Q data
No 10-Q data
No 10-Q data

HCM Metrics — Point-in-Time

No 10-Q data
No 10-Q data

HCM Metrics — Flow (Annual / YTD)

No 10-K data

Workforce Actions

Period EndTypeStatusAffected% WorkforceAnnouncedExpected CompletionGeographySegment / FunctionChargeSourceNote
2025-12-27plant_closurecompletedManchester, EnglandDiagnostics manufacturingMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Manufacturing facility ceased production in mid-November 2025; period costs from fixed overhead incurred there. Related restructuring charges of $3.9M recorded in the quarter but no employee count disclosed.
2025-12-27restructuringin_progressUSD 4 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring charges of $3.9M in Q1 FY2026; no employee counts or completion dates disclosed in this filing.
2025-12-27restructuringin_progressManchester, EnglandManufacturingUSD 3 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Cost of revenue adjustments related to shutdown of Manchester manufacturing location, primarily manufacturing period costs and retention benefits related to the merger.
2025-12-27restructuringin_progressUSD 4 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Total restructuring charges recorded for the quarter.
2025-12-27restructuringin_progressUSD 3,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-27plant_closurein_progress1392026-06-30United KingdomDiagnostics — molecular diagnostics manufacturingUSD 3 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Decision made during fiscal 2025 to shut down Manchester, England manufacturing (products also made in San Diego). $3.2M severance recorded in FY2025 of an estimated $6.0M total; works council negotiations finalized in Q4 FY2025. Also recorded $9.8M accelerated depreciation, primarily in cost of product revenues.
2025-09-27restructuringin_progress1182027-03-31United StatesDiagnostics R&D, Breast Health sales and service, Surgical R&D, CorporateUSD 7 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Fourth-quarter fiscal 2025 departmental reorganization; estimated total cost $8.1M. Majority of actions completed in Q4 FY2025; Surgical R&D action estimated to complete in the first half of fiscal 2027.
2025-09-27restructuringcompleted892025-06-28ChinaSales, across various divisionsUSD 4 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Third-quarter fiscal 2025 reorganization and cost reduction in China; action completed within the third quarter of fiscal 2025.
2025-09-27restructuringcompleted502025-03-29United StatesBreast Health, Surgical, and Corporate functionsUSD 5 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Second-quarter fiscal 2025 departmental reorganization; action completed within the second quarter of fiscal 2025.
2025-09-27plant_closurecompleted1902025-06-28Finland and FranceDiagnostics — Mobidiag businessUSD 3 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Program initiated in fiscal 2024 (closure of Finland and France facilities, development moved to San Diego); action completed in Q3 FY2025. Only the $3.4M severance recorded in FY2025 is captured here; total severance including accelerated stock compensation was $16.4M across fiscal 2024-2025.
2025-09-27plant_closurecompleted1172024-12-28United StatesBreast Health manufacturing (Danbury, Connecticut) and support functionsUSD 1 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Multi-year program initiated in fiscal 2022; transition completed in the first quarter of fiscal 2025. Only FY2025 severance of $1.4M captured; approximately 117 employees were terminated under the program in total, with $1.8M of site closure costs also recorded in FY2025.
2025-09-27acquisition_additioncompleted2025-01-022025-01-02United StatesGYN Surgicalbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Gynesonics, Inc. (Redwood City, California) completed January 2, 2025 for $340.7M; acquired headcount not disclosed. A $22.4M charge was recorded for acceleration of Gynesonics unvested stock options.
2025-09-27plant_closurein_progress1392025-09-272026-06-30Manchester, EnglandManufacturingUSD 3 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Shutdown of manufacturing operations. Severance charges recorded in Q4 FY2025. Action expected to be completed in first half of calendar 2026.
2025-09-27restructuringcompleted892025-06-282025-09-27ChinaSalesUSD 4 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Reorganization and cost reduction. Completed within Q3 FY2025.
2025-09-27restructuringin_progress1182025-09-272027-03-31United StatesDiagnostics, Breast Health, Surgical, CorporateUSD 7 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Reorganization of certain departments. Majority completed in Q4 FY2025; Surgical R&D action estimated to be completed by first half of FY2027.
2025-09-27restructuringcompleted502025-03-292025-06-28United StatesBreast Health, Surgical, CorporateUSD 5 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Reorganization and cost reduction. Completed within Q2 FY2025.
2025-09-27restructuringcompleted1902024-09-292025-06-28Finland, FranceDiagnostics (Mobidiag)USD 16 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Closure of Mobidiag facilities and transfer of operations to San Diego. Completed in Q3 FY2025. Total severance charges including accelerated stock compensation were $16.4 million.
2025-09-27restructuringin_progressUSD 28,600,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-09-27restructuringin_progressCurrent Fiscal Year Action [Member] / Current Fiscal Year charges [Member]USD 22,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-09-27restructuringin_progressPrevious Fiscal Year Action [Member] / Current Fiscal Year charges [Member]USD 3,400,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-09-27restructuringin_progressPrevious Two Fiscal Years Action [Member] / Current Fiscal Year charges [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-09-27restructuringin_progressOther Action [Member] / Current Fiscal Year charges [Member]USD 3,200,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-09-27restructuringin_progressCurrent Fiscal Year charges [Member]USD 28,600,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-09-27restructuringin_progressFacility Closing [Member] / Danbury, Connecticut [Member]USD 1,800,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-09-27restructuringin_progress139UNITED KINGDOMrestructuring_footnote
f5-10k / no-ai-xblr
2025-09-27restructuringin_progress118Q4 Fiscal 2025 Action [Member]restructuring_footnote
f5-10k / no-ai-xblr
2025-09-27plant_closurein_progressUnited KingdomManufacturing (Manchester facility)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Closure of the Manchester, UK manufacturing facility is referenced among items excluded from adjusted EPS (inventory write-offs and accelerated depreciation). No employee count, charge amount, or timeline is disclosed in this amendment.
2025-09-27acquisition_additioncompletedother
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Gynesonics acquisition executed during fiscal 2025; referenced repeatedly in STIP/PSU metric definitions and CEO performance outcomes. Headcount added through the acquisition is not disclosed in this amendment.
2025-09-27otherannounced2025-10-21subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Merger agreement with Hopper Parent Inc. dated October 21, 2025 (after fiscal year-end). Equity acceleration, option cancellation/CVR treatment, and cash retention awards to four NEOs ($2.25M aggregate) disclosed; no workforce reduction quantified.
2025-06-28restructuringcompleted852025-06-28ChinaVarious divisions and departmentsUSD 4 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Decision made during Q3 FY2025 to reorganize and reduce costs in China; action completed within the quarter. Severance recorded under ASC 420/ASC 712.
2025-06-28restructuringcompleted502025-03-29United StatesBreast Health and Surgical divisions and Corporate functionsUSD 5 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 FY2025 action disclosed in this filing's restructuring footnote; completed as of March 29, 2025.
2025-06-28plant_closurecompleted1902025-06-28Finland and FranceDiagnostics (Mobidiag)USD 16 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Facility closures and employee terminations occurred in FY2024; the action was completed in Q3 FY2025 with total severance charges of $16.4M including accelerated stock compensation. Charge figure is program total, not the current-quarter charge.
2025-06-28restructuringcompleted852025-03-302025-06-28ChinaVarious divisions and departmentsUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Reorganization and cost reduction in China; action completed within the third quarter of fiscal 2025.
2025-06-28restructuringcompleted502024-12-292025-03-29United StatesBreast Health, Surgical divisions, and Corporate functionsUSD 5 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Reorganization of certain departments and cost reduction; actions completed within the second quarter of fiscal 2025.
2025-06-28restructuringcompleted1902023-12-302025-06-28Finland and FranceDiagnostics (Mobidiag business)USD 16 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Closure of Mobidiag facilities in Finland and France; transfer of development activities to San Diego. Total severance charges including accelerated stock compensation were $16.4 million. Action completed in the third quarter of fiscal 2025.
2025-06-28plant_closurecompleted1172022-03-262025-03-29United States (Danbury, Connecticut)Breast HealthUSD 9 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Closure of Danbury, Connecticut facility where Breast Health capital equipment products were manufactured. Manufacturing transferred to Newark, Delaware. Total severance charges, including retention, relocation and outplacement costs, were $9.0 million. Action completed in the first quarter of fiscal 2025.
2025-06-28restructuringin_progress85USD 6,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-29restructuringcompleted502025-03-29United StatesBreast Health and Surgical divisions and Corporate functionsUSD 5 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Departmental reorganization and cost reduction; $5.0M severance and benefits recorded in Q2 FY2025; actions completed as of 2025-03-29. Announcement date not disclosed.
2025-03-29restructuringin_progress1902025-09-27Finland and FranceDiagnostics (Mobidiag)USD 16 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Closure of Mobidiag facilities with transfer of operations to San Diego; $15.7M is total estimated program severance including accelerated stock compensation, of which $2.4M recorded YTD and $0.7M in Q2. Employees ceasing employment in phases; expected completion in second half of fiscal 2025. Announced in Q1 FY2024; exact date not disclosed.
2025-03-29plant_closurecompleted1172024-12-28Danbury, Connecticut, United StatesBreast Health manufacturing (transitioned to Newark, Delaware)USD 9 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Approximately 117 employees terminated; $9.0M is total estimated severance including retention, relocation and outplacement. Manufacturing transition completed in Q1 FY2025; $1.4M severance and $1.1M site closure costs recorded YTD/Q2 FY2025. Announced in Q1 FY2022; exact date not disclosed.
2025-03-29acquisition_additioncompleted2025-01-022025-01-02Redwood City, California, United StatesGYN SurgicalUSD 22 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Gynesonics acquisition completed for $340.7M purchase price; headcount added not disclosed. $22.4M charge for acceleration of unvested stock options upon change of control.
2025-03-29restructuringcompleted502025-03-292025-03-29United StatesBreast Health, Surgical, CorporateUSD 5 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Reorganization of departments in Breast Health and Surgical divisions and Corporate functions. Actions completed as of March 29, 2025.
2025-03-29restructuringin_progress1902024-01-012025-09-27Finland, FranceDiagnostics (Mobidiag)USD 16 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Closure of Mobidiag facilities in Finland and France; transfer of development to San Diego. Expected to be completed in the second half of fiscal 2025.
2025-03-29restructuringin_progress1172022-01-012025-09-27Connecticut, United StatesBreast HealthUSD 9 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Closure of Danbury, Connecticut facility. Manufacturing transferred to Newark, Delaware. Transition completed in Q1 FY2025, but severance charges continue.
2025-03-29restructuringin_progress50USD 7,400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-12-28plant_closurein_progress1902023-10-012025-09-30Finland and FranceDiagnostics (Mobidiag)USD 16 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Mobidiag strategy change: closure of Finland and France facilities, relocation to San Diego. Total severance estimated at $15.5M; $1.7M recorded in Q1 FY2025. Announcement date reflects fiscal Q1 2024 decision period (approximate).
2024-12-28plant_closurecompleted2021-10-012024-12-28United States (Danbury, Connecticut)Breast Health manufacturingUSD 9 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Danbury facility closure; manufacturing transition to Newark, DE completed in Q1 FY2025. Total severance/retention/relocation estimated at $8.8M; $1.1M recorded in Q1 FY2025. Employees notified in fiscal Q1 2022 (announcement date approximate).
2024-12-28acquisition_additioncompleted2024-07-252024-07-25United KingdomBreast Health (Endomag)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Endomagnetics Ltd for $313.9M completed July 25, 2024; headcount added not disclosed.
2024-12-28acquisition_additionannounced2025-01-022025-01-02United States (Redwood City, California)GYN Surgical (Gynesonics)USD 350 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Gynesonics completed January 2, 2025 (post-quarter) for ~$350.0M; headcount added not disclosed.
2024-12-28restructuringin_progress1902024-03-302025-09-27Finland and FranceDiagnostics (Mobidiag)USD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Closure of Mobidiag facilities in Finland and France; 190 employees terminated. $1.7M severance recorded in Q1 FY25. Total estimated severance ~$15.5M. Expected completion in second half of fiscal 2025.
2024-12-28restructuringin_progress2022-03-302025-03-29United States (Danbury, Connecticut)Breast HealthUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Closure of Danbury, CT facility. Manufacturing transferred to Newark, DE. $1.1M severance recorded in Q1 FY25. Total estimated charges ~$8.8M. Transition completed in Q1 FY25.
2024-12-28acquisition_additioncompleted2024-07-25United KingdomBreast Healthbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Endomagnetics Ltd (Endomag). Headcount not explicitly disclosed.
2024-12-28acquisition_additioncompleted2025-01-02United States (California)GYN Surgicalsubsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Gynesonics, Inc. completed Jan 2, 2025. Headcount not explicitly disclosed.
2024-12-28restructuringin_progressUSD 3,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-28restructuringin_progress19020232025-03Finland and FranceDiagnostics (Mobidiag business)USD 32 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Q1 fiscal 2024 strategy change discontinued manufacture and sale of certain Mobidiag products, closed Finland and France facilities and moved development to San Diego, terminating 190 employees. Fiscal 2024 charges of $31.6M comprise a $12.5M lease impairment, $7.2M accelerated depreciation and $11.9M severance (recorded to date against an estimated total severance of approximately $13.9M). Completion expected by Q2 fiscal 2025.
2024-09-28reduction_in_forcecompleted3420242024-09-28Primarily Breast Health and Diagnostics segments; sales, marketing and research and development functionsUSD 4 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Various fiscal 2024 cost-containment decisions terminating approximately 34 employees; $3.9M of severance benefits recorded under ASC 420. Company states actions were completed as of September 28, 2024.
2024-09-28plant_closurein_progress20212025-06Danbury, Connecticut, United StatesBreast Health (manufacturing transfer to Newark, Delaware)USD 4 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year program announced in Q1 fiscal 2022 to close the Danbury manufacturing facility and transfer Breast Health capital equipment manufacturing to Newark, Delaware. Fiscal 2024 severance and benefits charges of $3.9M ($4.4M total fiscal 2024 restructuring charges including $0.5M other costs); total program severance, retention, relocation and outplacement costs estimated at approximately $8.6M. Transition expected complete by Q3 fiscal 2025.
2024-09-28plant_closurein_progress1902023-10-012025-02-28Finland and FranceDiagnostics (Mobidiag)USD 32 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Closure of Mobidiag facilities in Finland and France with relocation of development to San Diego; charge includes impairment, accelerated depreciation, and severance; severance charges of $11.9M recorded in FY2024; expected completion Q2 FY2025
2024-09-28restructuringcompleted342023-10-012024-09-28United StatesBreast Health and Diagnostics (sales, marketing, R&D)USD 4 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cost containment actions terminating approximately 34 employees; completed as of fiscal year-end
2024-09-28plant_closurein_progress2021-10-012025-08-31United StatesBreast Health (Danbury, Connecticut facility)USD 4 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Multi-year Danbury facility closure with manufacturing transfer to Newark, Delaware; $3.9M severance recorded in FY2024; total program estimated at $8.6M; expected completion Q3 FY2025
2024-09-28acquisition_additioncompleted2024-07-252024-07-25United KingdomBreast Healthbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Endomagnetics Ltd completed July 25, 2024; headcount not disclosed
2024-09-28divestiture_reductioncompleted2023-09-282023-10-03GlobalBreast Health (SSI ultrasound imaging)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of SSI ultrasound imaging business completed October 3, 2023; headcount not disclosed
2024-09-28acquisition_additionannounced2024-10-11United StatesGYN Surgicalsubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Gynesonics for approximately $350.0M announced October 11, 2024; pending regulatory approvals; headcount not disclosed
2024-09-28restructuringin_progress1902024-03-302025-06-29Finland and FranceDiagnostics (Mobidiag business)USD 32 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Closure of facilities in Finland and France; moving development activities to San Diego. Charge includes impairment, accelerated depreciation, and severance. Expected to be completed by Q2 FY2025.
2024-09-28restructuringcompleted342024-09-282024-09-28GlobalBreast Health and Diagnostics (Sales, Marketing, R&D)USD 4 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Cost containment decisions to terminate approximately 34 employees. Completed as of September 28, 2024.
2024-09-28restructuringin_progress2022-03-312025-09-27United States (Danbury, CT to Newark, DE)Breast Health (Manufacturing, R&D, Sales, Admin)USD 4 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Closure of Danbury facility. Transition expected to be completed by Q3 FY2025. $3.9M recorded in FY2024 for severance and benefits.
2024-09-28restructuringin_progressUSD 41,100,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-09-28restructuringin_progressRestructuring Charges [Member] / Current Fiscal Year Action [Member] / Current Fiscal Year charges [Member]USD 36,700,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-09-28restructuringin_progressRestructuring Charges [Member] / Previous Fiscal Year Action [Member] / Current Fiscal Year charges [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-09-28restructuringin_progressRestructuring Charges [Member] / Previous Two Fiscal Years Action [Member] / Current Fiscal Year charges [Member]USD 4,400,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-09-28restructuringin_progressRestructuring Charges [Member] / Other action [Member] / Current Fiscal Year charges [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-09-28restructuringin_progressRestructuring Charges [Member] / Current Fiscal Year charges [Member]USD 41,100,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-09-28restructuringin_progress34Various Locations [Member]restructuring_footnote
f5-10k / no-ai-xblr
2024-06-29plant_closurein_progress1902023-10-012025-03-31Finland and FranceDiagnostics (Mobidiag)USD 13 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Mobidiag strategy change: discontinued certain products, closed Finland and France facilities, moved development to San Diego. Severance charges of $3.9M in Q3 and $7.9M YTD; total estimated severance ~$13.1M. Works Council negotiations finalized in Q2 FY2024; action expected complete by Q2 FY2025.
2024-06-29plant_closurein_progress2021-10-012025-06-30United States (Danbury, Connecticut)Breast Health manufacturingUSD 8 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Danbury facility closure with transfer of manufacturing to Newark, Delaware. Severance charges of $0.9M in Q3 and $2.7M YTD; total severance including retention estimated at ~$7.5M. Employees notified in Q1 FY2022; transition expected complete by Q3 FY2025.
2024-06-29acquisition_additioncompleted2024-04-262024-07-25United KingdomBreast HealthUSD 310 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Endomagnetics Ltd (Endomag) for ~$310.0M; closed July 25, 2024 (subsequent to quarter end). Headcount added not disclosed.
2024-06-29divestiture_reductioncompleted2023-09-292023-10-03InternationalBreast Health (SSI ultrasound imaging)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of SSI ultrasound imaging business completed October 3, 2023 (start of fiscal 2024). Headcount removed not disclosed.
2024-06-29restructuringin_progress1902024-03-302025-06-30Finland and FranceDiagnostics (Mobidiag)USD 13 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Strategy change included discontinuing manufacture/sale of certain products and closure of facilities. Total estimated severance charges approx $13.1 million. Action expected to be completed by Q2 FY2025.
2024-06-29restructuringin_progress2022-03-312025-09-30United States (Danbury, CT)Breast HealthUSD 8 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Closure of Danbury, CT facility. Manufacturing transferring to Newark, DE. Total estimated severance charges approx $7.5 million. Transition expected to be completed by Q3 FY2025.
2024-06-29restructuringin_progressUSD 6,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-30restructuringin_progress1902023-12-302025-03-31Finland and FranceDiagnostics (Mobidiag)USD 12 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Mobidiag strategy change: discontinued certain products, closed Finland and France facilities, moved operations to San Diego. Severance includes accelerated stock compensation; $4.0M recorded in Q2 FY2024. Also recorded $7.2M accelerated depreciation and $12.5M lease asset impairment in Q1 FY2024.
2024-03-30plant_closurein_progress2021-10-012025-06-30United States (Danbury, Connecticut)Breast Health (manufacturing)USD 8 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Danbury facility closure ongoing since FY2022; manufacturing transferring to Newark, Delaware. Total severance including retention estimated at $7.5M. $1.8M severance recorded in six months ended March 30, 2024. Employee count not disclosed.
2024-03-30restructuringin_progress1902024-03-302025-06-30Finland and FranceDiagnostics (Mobidiag)USD 12 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Strategy change for Mobidiag business including closure of facilities in Finland and France. Total estimated severance charges approx $12.2 million. $4.0 million recorded in Q2 2024. Expected completion by Q2 FY2025.
2024-03-30restructuringin_progress2022-01-012025-09-30United States (Danbury, CT)Breast HealthUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Closure of Danbury, CT facility. Manufacturing transferring to Newark, DE. $1.8 million severance recorded in Q2 2024. Total estimated charges approx $7.5 million. Expected completion by Q3 FY2025.
2024-03-30restructuringin_progressUSD 6,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-12-30restructuringin_progress2024-12-31International (Works Council jurisdictions)DiagnosticsUSD 4 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Strategy change led to product discontinuation and facility closures; includes $7.2M accelerated depreciation and $12.5M lease asset impairment. Minimum statutory severance of $1.8M recorded this quarter; total severance expected $4.0M–$8.0M. Employee headcount not disclosed.
2023-12-30plant_closurein_progress2021-10-012025-06-30United States (Danbury, Connecticut; relocating to Newark, Delaware and Marlborough, Massachusetts)Breast Health manufacturing and corporate functionsUSD 6 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Long-running Danbury facility closure initiated in fiscal 2022; $0.5M severance and $0.5M facility restoration costs recorded this quarter. Total severance including retention estimated at $5.9M. Most employees offered relocation; headcount not disclosed.
2023-12-30divestiture_reductioncompleted2023-09-292023-10-03InternationalBreast Health — SuperSonic Imagine ultrasound imaging businessother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of SSI ultrasound business completed October 3, 2023; $51.7M impairment recorded in fiscal 2023 Q4. Headcount transferred not disclosed.
2023-12-30restructuringin_progress2023-10-012024-12-31GlobalDiagnosticsUSD 22 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Strategy change in Diagnostics including product discontinuation and facility closures. Charges include $7.2M accelerated depreciation, $12.5M lease asset impairment, and $1.8M statutory severance. Total expected severance $4.0M-$8.0M. Employee count not disclosed.
2023-12-30restructuringin_progress2022-10-012025-06-30United StatesBreast HealthUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Closure of Danbury, CT facility. Charges include $0.5M severance and $0.5M facility restoration. Total estimated severance $5.9M. Employee count not disclosed.
2023-12-30divestiture_reductioncompleted2023-09-292023-10-03GlobalBreast Healthbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Sale of SuperSonic Imagine (SSI) ultrasound imaging business. Employee count not disclosed.
2023-12-30restructuringin_progressUSD 22,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringcompleted1282023-09-30Multiple (U.S. and international; includes consolidation/closure of certain offices in Germany and transfer of U.S. warehouse distribution to a third-party facility)All divisions / multiple departmentsUSD 9 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Approximately 128 terminations are cumulative across decisions made in fiscal 2022 and fiscal 2023; charges recorded were $9.4 million in fiscal 2023 and $0.3 million in fiscal 2022, primarily severance, under ASC 712/ASC 420. Filer states actions were completed as of September 30, 2023.
2023-09-30plant_closurein_progress111Danbury, Connecticut to Newark, Delaware (United States)Breast Health capital equipment manufacturing; R&D, sales/service support and administrative functions relocating to Newark, DE and Marlborough, MAUSD 2 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Closure decision finalized in Q1 fiscal 2022 (employees notified then; informed of termination and severance in Q3 fiscal 2022). Severance recorded ratably over required service period per ASC 420: $2.1 million in fiscal 2023 plus $1.6 million in fiscal 2022; total program severance and benefits, including retention, expected at approximately $5.9 million for 111 expected terminations. Transition expected to be completed by Q2 fiscal 2025.
2023-09-30restructuringin_progress1282023-09-30Global (multiple divisions); includes Germany office closures and U.S. warehouse distribution transferMultiple departments across all divisionsUSD 9 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Approximately 128 employees terminated across fiscal 2023 and fiscal 2022 combined; $9.4M severance recorded in fiscal 2023 and $0.3M in fiscal 2022. Also included consolidation/closure of certain Germany offices and transfer of U.S. warehouse distribution to a third party. Actions completed as of September 30, 2023.
2023-09-30plant_closurein_progress1112021-10-012024-12-31Danbury, Connecticut, United StatesBreast Health capital equipment manufacturing; R&D, sales/service support, and administrative functions relocating to Newark, DE and Marlborough, MAUSD 2 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Danbury facility closure decision finalized in fiscal 2022 Q1; $2.1M severance recorded in fiscal 2023 ($1.6M in fiscal 2022). Total expected severance and benefits including retention approximately $5.9M. Transition expected to complete by fiscal 2025 Q2. Announcement date approximate (fiscal 2022 Q1).
2023-09-30acquisition_additioncompleted2023-07-032023-07-03South KoreaBreast Health (distribution)USD 7 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of JW Medical Corporation distributor assets; purchase price $6.7M. No headcount disclosed.
2023-09-30acquisition_additioncompleted2023-04-032023-04-03Nordic region of EuropeGYN Surgical (distribution)USD 8 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Normedi Nordic AS distributor; purchase price $7.7M including $1.1M contingent consideration. No headcount disclosed.
2023-09-30divestiture_reductioncompleted2023-09-282023-10-03Global (SSI ultrasound imaging business)Breast Health (ultrasound imaging)USD 52 (millions)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Agreement to sell SSI ultrasound imaging business for $1.9M cash; sale completed October 3, 2023 (subsequent to fiscal year-end). $51.7M held-for-sale charge recorded in fiscal 2023 Q4. No employee headcount disclosed.
2023-09-30restructuringcompleted1282023-09-30GlobalAll DivisionsUSD 12 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Fiscal 2023 actions included termination of approximately 128 employees across all divisions, office consolidations/closures in Germany, and warehouse transfer in the US. Actions completed as of September 30, 2023.
2023-09-30plant_closurein_progress1112022-10-012025-06-30United StatesBreast HealthUSD 2 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Closure of Danbury, Connecticut facility. Manufacturing and support services moving to Newark, Delaware. 111 employees expected to be terminated. Total expected charges approx $5.9 million. $2.1 million recorded in fiscal 2023.
2023-09-30restructuringin_progressUSD 12,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-09-30restructuringin_progress128Various Locations [Member]restructuring_footnote
f5-10k / no-ai-xblr
2023-09-30restructuringin_progress111Danbury, Connecticut [Member]restructuring_footnote
f5-10k / no-ai-xblr
2023-07-01plant_closurein_progress2021-12-252024-03-31Danbury, Connecticut, United StatesBreast Health manufacturing; R&D, sales and services support, and administrative functionsUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Charge shown is nine months ended 2023-07-01 ($0.4M in the quarter). Total severance including retention estimated at ~$5.0M. Employees notified of closure in Q1 FY2022; termination benefits communicated in Q3 FY2022. No employee count disclosed.
2023-07-01restructuringin_progress2021-09-262023-09-30Germany; United StatesMultiple departments across all divisions; office consolidation and warehouse distribution transferUSD 4 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Charge shown is nine months ended 2023-07-01 ($1.7M in the quarter). Total severance for these actions estimated at ~$5.0M. Covers personnel terminations across divisions, consolidation/closure of certain German offices, and transfer of US warehouse distribution to a third party. No employee count disclosed.
2023-07-01acquisition_additioncompleted2023-04-032023-04-03Nordics region of EuropeGYN Surgical (distribution)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Normedi Nordic AS completed 2023-04-03 for $7.7M purchase price; distributor of Surgical products. No headcount added disclosed.
2023-07-01restructuringin_progress2022-01-012025-06-30United StatesBreast HealthUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Closure of Danbury, CT facility; manufacturing moving to Newark, DE. Charges recorded ratably over required service period. Total estimated severance ~$5.0 million.
2023-07-01restructuringin_progress2022-01-012023-09-30GlobalAll DivisionsUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Termination of personnel across all divisions, consolidation/closure of offices in Germany, and transfer of US warehouse distribution to third-party. Total estimated severance ~$5.0 million.
2023-07-01restructuringin_progressUSD 2,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-07-01restructuringin_progressDanbury closure [Member]USD 400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-07-01restructuringin_progressOther action [Member]USD 1,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-04-01plant_closurein_progress2021-10-012025-06-30United StatesBreast Health (manufacturing) and corporate support functionsUSD 6 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Danbury, Connecticut facility closure announced in Q1 FY2022; manufacturing moving to Newark, Delaware. Severance charges of $0.3M (three months) and $1.0M (six months) recorded this period; total estimated severance including retention approximately $5.5M. No employee count disclosed.
2023-04-01restructuringin_progress2022-10-012023-09-30GermanyAll divisions; multiple departmentsUSD 4 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Consolidation and closure of certain offices in Germany with terminations across all divisions. Charges of $1.5M (three months) and $1.9M (six months) recorded this period; total estimated severance approximately $3.9M. No employee count disclosed.
2023-04-01restructuringin_progress2022-01-012025-09-30United StatesBreast HealthUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Closure of Danbury, CT facility. Majority of employees offered relocation; those not relocating terminated. Charges recorded for three months ended April 1, 2023.
2023-04-01restructuringin_progress2023-01-012023-09-30GermanyAll divisionsUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Consolidation and closure of certain offices in Germany. Charges recorded for three months ended April 1, 2023.
2023-04-01restructuringin_progressUSD 1,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-04-01restructuringin_progressDanbury closure [Member]USD 300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-04-01restructuringin_progressGermany Plan [Member]USD 1,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-12-31plant_closurein_progress2021-10-012025-06-30United States — Danbury, ConnecticutBreast Health manufacturing; R&D, sales/service support and administrative functions relocating to Newark, Delaware and Marlborough, MassachusettsUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Decision finalized in Q1 FY2022; employees notified then but severance communicated in Q3 FY2022. $0.7M severance charge recorded in Q1 FY2023; $1.6M in FY2022; total estimated severance including retention ~$7.0M. Number of affected employees not disclosed. Transition expected complete by Q3 FY2025.
2022-12-31restructuringin_progress2022-03-272025-09-30United StatesBreast HealthUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Closure of Danbury, CT facility. Majority of employees offered relocation; those not relocating terminated. Total expected severance charges approx $7.0 million. $0.7 million recorded in Q1 FY2023.
2022-12-31restructuringin_progressUSD 1,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-12-31restructuringin_progressDanbury closure [Member]USD 700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-09-24plant_closurein_progress2021-12-012025-06-30United States — Danbury, ConnecticutBreast Health manufacturing; R&D, sales/service support and administrative functionsUSD 2 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2022 severance charge of $1.6M; total program severance and benefits including retention estimated at ~$7.0M. Employees notified in fiscal Q1 2022; terminations and severance communicated in fiscal Q3 2022. Manufacturing moving to Newark, Delaware; transition expected complete by fiscal Q3 2025. No employee count disclosed.
2022-09-24restructuringin_progress2021-12-01United States and international locationsMultiple divisions and departmentsUSD 1 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2022 charges of $0.3M severance and benefits plus $0.5M property closure costs for workforce terminations, outsourcing of one U.S. distribution location, and consolidation of German office locations. Total expected charges for these actions approximately $3.5M. No employee count disclosed.
2022-09-24acquisition_additioncompleted2021-11-292021-11-29United States — Louisville, ColoradoGYN SurgicalUSD 160 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Purchase price of $160.1M; acquired headcount not disclosed. Management excluded Bolder internal controls from its FY2022 ICFR assessment.
2022-09-24restructuringin_progress2022-01-012025-09-30United StatesBreast HealthUSD 2 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Closure of Danbury, CT facility. Transition expected to complete by Q3 FY2025. Total estimated charges approx $7.0 million; $1.6 million recorded in FY2022.
2022-09-24restructuringcompleted2022-01-012022-09-24GlobalVariousUSD 1 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Various terminations, outsourcing of US distribution location, and consolidation of German offices. Total estimated charges approx $3.5 million; $0.3 million severance and $0.5 million property closure costs recorded in FY2022.
2022-09-24restructuringin_progressUSD 2,400,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-06-25plant_closurein_progressUnited States (Danbury, Connecticut; relocating to Newark, Delaware and Marlborough, Massachusetts)Breast Health manufacturing, plus R&D, sales/service support and administrative functionsUSD 7 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Decision to close the Danbury, CT facility finalized in fiscal Q1 2022; employees notified of closure in Q1 FY2022 but informed of terminations and severance in Q3 FY2022, when $0.8M of severance and benefits was recorded. Company estimates total severance and benefits charges, including retention, of approximately $7.0M. Transition expected to complete by fiscal Q3 2025; no employee count or exact announcement date disclosed.
2022-06-25restructuringin_progress2022-01-012025-09-25United StatesBreast HealthUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Closure of Danbury, CT facility. Majority of employees offered relocation; those not relocating will be terminated. Total expected severance/benefits charges approx $7.0 million. $0.8 million charged in Q3 FY2022.
2022-06-25restructuringin_progressUSD 800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-03-26plant_closurein_progress2021-10-012025-06-30Danbury, Connecticut, United StatesBreast Health manufacturing; R&D, sales/service support, and administrative functionsUSD 10 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Decision finalized in Q1 FY2022; employees notified but severance not yet communicated, so no charge recorded yet. Estimated total severance and benefits, including retention, ~$10.0M to be recorded ratably once communication date is met. Transition expected complete by Q3 FY2025.
2022-03-26acquisition_additioncompleted2021-11-292021-11-29Louisville, Colorado, United StatesGYN Surgicalbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Bolder Surgical Holdings completed 2021-11-29 for $160.1M purchase price; headcount added not disclosed.
2022-03-26restructuringin_progress2022-01-012025-09-30United StatesBreast HealthUSD 10 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Closure of Danbury, CT facility. Employees notified in Q1 FY2022; termination/severance not yet communicated. Total severance/benefits estimated at $10.0M to be recorded ratably once communication date is met.
2022-03-26restructuringin_progressUSD -200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-12-25plant_closureannounced2021-12-252025-06-30Danbury, Connecticut, United StatesBreast Health manufacturing; R&D, sales/service support and administrative functionsUSD 13 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Decision finalized in Q1 FY2022 to close the Danbury facility and move Breast Health capital equipment manufacturing to Newark, Delaware. Employees were notified during the quarter but severance terms were not yet communicated, so no charge was recorded under ASC 420. Estimated total severance and benefits charges, including retention, approximately $13.0 million, to be recorded ratably once the communication date is met. Transition expected complete by Q3 fiscal 2025.
2021-12-25acquisition_additioncompleted2021-11-292021-11-29Louisville, Colorado, United StatesGYN Surgicalbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Bolder Surgical Holdings, Inc. for $160.1 million purchase price, completed November 29, 2021. No headcount added disclosed.
2021-12-25restructuringannounced2021-12-252025-06-30United StatesBreast HealthUSD 13 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Closure of Danbury, CT facility. Majority of employees offered relocation to Newark, DE or Marlborough, MA by March 2022. Termination charges expected to be recorded ratably once communication date is met.
2021-12-25restructuringin_progressUSD 200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-09-25restructuringcompletedUnited States and international locationsAll divisions; multiple departmentsUSD 9 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2021 program: $8.7M severance and benefits for terminations across all divisions plus closure of certain manufacturing facilities for minor product lines; total FY2021 charge $9.3M. Employee count not disclosed. Accrued restructuring balance at year-end was $4.1M.
2021-09-25acquisition_additioncompleted2021-06-172021-06-17FinlandDiagnosticsUSD 730 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Purchase price, not a workforce charge. Acquired headcount not disclosed.
2021-09-25acquisition_additioncompleted2021-02-222021-02-22United States (San Diego, California)DiagnosticsUSD 231 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Purchase price, not a workforce charge. Acquired headcount not disclosed.
2021-09-25acquisition_additioncompleted2021-03-012021-03-01BelgiumDiagnosticsUSD 155 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Purchase price, not a workforce charge. Acquired headcount not disclosed.
2021-09-25acquisition_additioncompleted2020-12-302020-12-30GermanyBreast HealthUSD 63 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Purchase price, not a workforce charge. Acquired headcount not disclosed.
2021-09-25acquisition_additionannounced2021-10-142021-12-31United States (Louisville, Colorado)GYN SurgicalUSD 160 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Announced after fiscal year-end; expected to close before end of calendar 2021, subject to regulatory approvals. Purchase price, not a workforce charge; headcount not disclosed.
2021-09-25restructuringcompleted2021-01-012021-09-25GlobalAll divisionsUSD 9 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Fiscal 2021 actions: termination of certain individuals across all divisions and closure of certain manufacturing facilities for minor product lines. Charge recorded for severance and benefits.
2021-09-25acquisition_additioncompleted2021-06-172021-06-17FinlandDiagnosticsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Mobidiag Oy. Employee count not explicitly disclosed in footnote.
2021-09-25acquisition_additioncompleted2021-02-222021-02-22United StatesDiagnosticsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Biotheranostics, Inc. Employee count not explicitly disclosed in footnote.
2021-09-25acquisition_additioncompleted2021-03-012021-03-01BelgiumDiagnosticsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Diagenode SA. Employee count not explicitly disclosed in footnote.
2021-09-25acquisition_additioncompleted2020-12-302020-12-30GermanyBreast Healthbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Somatex Medical Technologies GmbH. Employee count not explicitly disclosed in footnote.
2021-09-25restructuringin_progressUSD 9,300,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-06-26restructuringin_progressUSD 4 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Charges primarily related to severance benefits for cost reduction initiatives aligning cost structure with operations.
2021-06-26restructuringin_progressUSD 7 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Year-to-date charges primarily related to severance benefits for cost reduction initiatives.
2021-06-26restructuringin_progressUSD 3,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-03-27restructuringin_progressUSD 3 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance-related charges of $3.0M for six months ended 2021-03-27 ($1.6M for the quarter), primarily severance benefits; number of employees affected not disclosed.
2021-03-27acquisition_additioncompletedGermanyBreast HealthUSD 63 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition completed 2020-12-30 for $62.8M purchase price; acquired headcount not disclosed.
2021-03-27acquisition_additioncompletedUnited StatesDiagnosticsUSD 233 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition completed 2021-02-22 for $232.5M purchase price; acquired headcount not disclosed.
2021-03-27acquisition_additioncompletedBelgiumDiagnosticsUSD 153 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition completed 2021-03-01 for $153.4M purchase price; acquired headcount not disclosed.
2021-03-27acquisition_additionannounced2021-04-08Finland; FranceDiagnosticsUSD 795 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to acquire Mobidiag announced 2021-04-08 for approximately $795M; expected to close in Q4 fiscal 2021, subject to regulatory approvals; acquired headcount not disclosed.
2021-03-27restructuringcompletedUSD 2 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Charges primarily related to severance benefits for the three months ended March 27, 2021. Employee count not disclosed.
2021-03-27restructuringcompletedUSD 3 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Charges primarily related to severance benefits for the six months ended March 27, 2021. Employee count not disclosed.
2021-03-27acquisition_additioncompleted2021-02-22San Diego, CaliforniaDiagnosticsbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Biotheranostics, Inc. Headcount not explicitly disclosed.
2021-03-27acquisition_additioncompleted2021-03-01BelgiumDiagnosticsbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Diagenode SA. Headcount not explicitly disclosed.
2021-03-27acquisition_additioncompleted2020-12-30GermanyBreast Healthbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Somatex Medical Technologies GmbH. Headcount not explicitly disclosed.
2021-03-27otherannounced2021-04-082021-12-31Finland and FranceDiagnosticssubsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Agreement to acquire Mobidiag Oy for approx $795 million. Expected to close in Q4 FY2021. Headcount impact not disclosed.
2021-03-27restructuringin_progressUSD 1,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-12-26restructuringin_progressUSD 1 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 FY2021 charge of $1.4M primarily for severance benefits from ongoing cost-reduction initiatives; no employee counts or timing disclosed.
2020-12-26acquisition_additioncompleted2020-12-302020-12-30GermanyBreast HealthUSD 64 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Somatex Medical Technologies GmbH (biopsy site markers, Tumark line) for approximately $64.0 million, completed four days after quarter end; headcount added not disclosed.
2020-12-26acquisition_additionannounced2021-01-05United StatesDiagnosticsUSD 230 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to acquire Biotheranostics, Inc. (San Diego, CA; molecular diagnostic tests for breast and metastatic cancers) for approximately $230.0 million, subject to regulatory approvals; headcount not disclosed.
2020-12-26restructuringcompletedUSD 1 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Charges primarily related to severance benefits from cost reduction initiatives.
2020-12-26othercompleted2020-04-012020-09-26GlobalMD&A
f5-10q / Qwen3.6-27B-Q8_0		Cost-cutting measures initiated in April 2020 included employee furloughs, salary cuts, reduced hours, and terminations. Measures ceased by end of Q3 FY2020.
2020-12-26restructuringin_progressUSD 1,400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-26restructuringin_progressMultipleAll divisions; multiple departmentsUSD 15 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2020 program: personnel terminations across all divisions, production transfers and closure of certain manufacturing facilities for minor product lines. Severance and benefits charges of $13.4M (including $5.0M equity award modification for one executive) plus $1.9M net divestiture charges. Headcount affected not disclosed. Additional charges of about $1.7M expected over the next twelve months.
2020-09-26plant_closurein_progressUnited States — Sunnyvale, CADiagnostics — Perinatal productionrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Closure of the Sunnyvale, CA location as Perinatal production is transferred to San Diego; part of the $1.7M of additional expected charges. Headcount affected not disclosed.
2020-09-26divestiture_reductioncompleted2019-11-202019-12-30MultipleMedical Aesthetics segmentUSD 30 (millions)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of the Medical Aesthetics business to Clayton Dubilier & Rice completed 2019-12-30 for a final price of $150.0M; $30.2M held-for-sale impairment recorded in Q1 FY2020. Headcount removed not disclosed. Company retained indemnification obligations and provided transition services for up to 15 months.
2020-09-26acquisition_additioncompleted2020-08-23United States — Austin, TXGYN SurgicalUSD 161 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Purchase price of $161.3M including $81.8M contingent consideration. Headcount added not disclosed; excluded from management's ICFR assessment as less than 1% of total assets and revenues.
2020-09-26acquisition_additioncompleted2020-02-03United StatesBreast HealthUSD 20 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Purchase price $19.7M including $2.3M hold-back. Headcount added not disclosed.
2020-09-26acquisition_additioncompleted2019-12-30United StatesBreast Health and Skeletal Health (distributor)USD 18 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Asset purchase of a long-standing U.S. distributor for $18.0M. Headcount added not disclosed.
2020-09-26acquisition_additioncompleted2019-08-012019-11-21France (Aix-en-Provence)Breast HealthUSD 69 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Control obtained 2019-11-21 at ~78% ownership (approximately 81% by 2020-09-26); total accounting purchase price $69.3M. Headcount added not disclosed; noncontrolling interest of $4.7M recorded against net income in FY2020.
2020-09-26restructuringcompleted2020-04-012020-09-26GlobalAll divisionsUSD 15 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Fiscal 2020 actions included workforce reductions and divestiture charges. Employee cost-cutting measures (furloughs, salary cuts, terminations) ceased substantially by end of Q3. Charge includes $13.4M severance and $1.9M divestiture charges.
2020-09-26divestiture_reductioncompleted2019-11-202019-12-30GlobalMedical Aestheticsdiscontinued_operations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Sale of Medical Aesthetics business completed Dec 30, 2019. Headcount removed not explicitly quantified in employee count, but segment eliminated from operations.
2020-09-26restructuringin_progressUSD 15,300,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-06-27restructuringcompletedGlobalAll divisionsUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Positions terminated company-wide in Q3 FY2020 due to the COVID-19 pandemic; charges recorded under ASC 712 or ASC 420 depending on the employee. Filer states no additional severance and benefits charges are expected under this action. No affected-employee count disclosed.
2020-06-27restructuringin_progressGlobalManufacturing and other operationsUSD 4 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Nine months ended June 27, 2020 charge of $3.9M (including $0.1M in Q3) covering decisions in Q2 and Q3 FY2020 to close certain manufacturing plant facilities, divest a business, and terminate certain personnel. Filer expects about $1.8M of additional charges over the next twelve months. No affected-employee count disclosed.
2020-06-27othercompleted2020-04-012020-06-27Primarily United StatesCompany-wideMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		April 2020 cost-cutting measures included employee furloughs, salary cuts (primarily U.S.), reduced hours, and some terminations, plus temporary manufacturing shutdowns and reduced work-week schedules. Filer states substantially all employee cost-cutting measures had ceased by quarter-end. No counts disclosed.
2020-06-27divestiture_reductioncompleted2019-11-202019-12-30GlobalMedical Aestheticsother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale to Clayton, Dubilier & Rice completed December 30, 2019 for $205.0M in cash (less adjustments); $153.4M proceeds received. Disposal footnote lists assets and liabilities transferred but discloses no employee counts. Company retained indemnification and transition-service obligations.
2020-06-27acquisition_additioncompleted2019-11-212019-11-21FranceBreast Health (ultrasound imaging)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Control obtained November 21, 2019 at approximately 78% ownership (about 81% at June 27, 2020); total purchase price $69.3M. Business combination footnote discloses no acquired headcount.
2020-06-27acquisition_additioncompleted2019-12-302019-12-30United StatesBreast Health and Skeletal Health distributionbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Asset acquisition of a long-standing U.S. distributor for $18.0M. No acquired headcount disclosed.
2020-06-27acquisition_additioncompleted2020-02-032020-02-03United StatesBreast Health (LOCalizer localization product)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Health Beacons, Inc. for $19.3M including hold-backs. No acquired headcount disclosed.
2020-06-27restructuringcompleted2020-04-01GlobalAll divisionsUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Termination of certain positions across all divisions due to COVID-19 pandemic. Charges recorded in Q3 FY2020. No additional severance expected.
2020-06-27restructuringin_progress2020-04-012021-06-27GlobalManufacturing and otherUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Closure of certain manufacturing plant facilities, divestiture of certain business, and termination of certain personnel. $0.1M charged in Q3, $3.9M charged YTD. Additional $1.8M expected over next 12 months.
2020-06-27othercompleted2020-04-012020-06-27United StatesAll functionsMD&A
f5-10q / Qwen3.6-27B-Q8_0		Implemented employee furloughs, salary cuts primarily in the U.S., reduced hours, and in certain instances employee terminations. Substantially all measures ceased by end of Q3.
2020-06-27restructuringin_progressUSD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-28divestiture_reductioncompleted2019-11-202019-12-30GlobalMedical AestheticsUSD 30 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale to Clayton Dubilier & Rice completed 2019-12-30; $30.2M held-for-sale impairment recorded in Q1 FY2020. Headcount not disclosed.
2020-03-28divestiture_reductioncompleted2020-01-012020-03-28Not disclosedLife sciences testing businessUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Research testing business for pharmaceutical companies disposed to managers of the operations during Q2 FY2020; headcount not disclosed.
2020-03-28restructuringcompleted2020-01-012020-03-28GlobalCorporate / variousUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Company decided to terminate certain positions in various parts of the world during Q2 FY2020; charges recorded under ASC 712 or ASC 420. Employee count not disclosed.
2020-03-28acquisition_additioncompleted2019-12-302019-12-30United StatesBreast Health / Skeletal Health distributionUSD 18 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Asset acquisition of Alpha Imaging, LLC distributor; purchase price $18.0M. Headcount added not disclosed.
2020-03-28acquisition_additioncompleted2020-02-032020-02-03United StatesBreast Health (Faxitron)USD 19 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Health Beacons, Inc. (LOCalizer product); purchase price $19.3M. Headcount added not disclosed.
2020-03-28otherannounced2020-04-01Primarily United StatesCompany-wideUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		April 2020 COVID-19 cost cutting: limited number of personnel terminated; severance expected to be recorded in Q3 FY2020. Count not disclosed.
2020-03-28otherannounced2020-04-012020-12-31United StatesManufacturing (Perinatal product transfer from Sunnyvale to San Diego)USD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Decision to transfer Perinatal product line; certain manufacturing personnel to be terminated, with severance charges through end of calendar 2020. Count not disclosed.
2020-03-28otherannounced2020-04-01Primarily United StatesCompany-wideMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		April 2020 measures included employee furloughs, salary cuts primarily in the U.S., reduced hours, and certain terminations, plus temporary manufacturing shutdowns and reduced work-week schedules. Counts not disclosed.
2020-03-28restructuringcompleted2020-03-282020-03-28Various parts of the worldVariousUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Termination of certain positions recorded in Q2 FY2020.
2020-03-28restructuringannounced2020-04-012020-06-30GlobalVariousUSD 1 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Cost-cutting measures related to COVID-19 pandemic; termination of limited personnel across the Company. Expected to record charges in Q3 FY2020.
2020-03-28restructuringannounced2020-04-012020-12-31United StatesManufacturingUSD 1 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Transfer of Perinatal product from Sunnyvale to San Diego facility; termination of certain manufacturing personnel. Expected to record charges through end of calendar 2020.
2020-03-28restructuringin_progressUSD 2,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-28restructuringin_progressTepnel [Member]USD 1,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-12-28restructuringin_progressUSD 1 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		MD&A discloses severance benefit charges of $0.9M for the quarter from cost reduction and integration initiatives, primarily employee terminations; no employee count, announcement date, or completion timeline disclosed.
2019-12-28divestiture_reductioncompleted2019-11-202019-12-30Medical AestheticsUSD 30 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of Medical Aesthetics business to Clayton Dubilier & Rice for $205.0M; $30.2M impairment recorded as assets held-for-sale. No headcount associated with the divested business disclosed.
2019-12-28acquisition_additioncompleted2019-11-212019-11-21FranceBreast Healthbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Company acquired additional 7.6M shares of SuperSonic Imagine on 2019-11-21, reaching ~78% ownership and consolidating results; no employee headcount added disclosed.
2019-12-28restructuringcompletedUSD 1 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Severance benefit charges of $0.9 million recorded in Q1 FY2020 related to cost reduction initiatives and integration activities.
2019-12-28divestiture_reductioncompleted2019-11-202019-12-30Medical AestheticsUSD 30 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Sale of Medical Aesthetics business completed Dec 30, 2019. Impairment charge of $30.2 million recorded to fair value less costs to sell. Employee count not disclosed.
2019-12-28restructuringin_progressUSD 900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-28restructuringin_progress242018-09-302019-12-28United States (Marlborough, MA) / Costa RicaShared services / general administrationUSD 4 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Transfer of shared services positions from Marlborough to Costa Rica; 24 personnel terminated plus other employee termination actions. Filer expects to finalize transition in Q1 fiscal 2020 with an additional $0.1M charge. Charge shown is fiscal 2019 workforce reduction charge only.
2019-09-28restructuringcompleted2017-09-302019-09-28Belgium, France, Italy, Spain, GermanyInternational accounting and customer service (consolidated to Manchester, UK)USD 1 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Multi-year program initiated in fiscal 2018; only the $1.2M charge recorded during fiscal 2019 is captured here. Transition completed in fiscal 2019.
2019-09-28plant_closurecompleted2018-06-302019-09-28United States (Hicksville, New York)Medical Aesthetics (Cynosure manufacturing)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Closure of the Hicksville facility manufacturing certain Cynosure products; employees notified in fiscal 2018. Only residual pro-rata charges recorded in fiscal 2019; headcount affected not disclosed.
2019-09-28divestiture_reductionannounced2019-11-202019-12-31GlobalMedical Aestheticssubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to sell the Medical Aesthetics business for $205M cash (net proceeds ~$138M) to Clayton Dubilier & Rice, signed after fiscal year-end. Headcount to be transferred not disclosed.
2019-09-28acquisition_additioncompleted2018-10-012018-10-01United States (California)Breast Healthbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Focal Therapeutics completed October 1, 2018 (first quarter of fiscal 2019) for $120.1M. Headcount added not disclosed.
2019-09-28acquisition_additionin_progress2019-08-012020-03-31FranceBreast Health (ultrasound imaging)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquired ~46% of SuperSonic Imagine on August 1, 2019; obtained voting control November 21, 2019 with ~78% ownership. Consolidation expected to begin November 21, 2019. Headcount added not disclosed.
2019-09-28restructuringcompleted242019-01-012020-03-31United StatesShared ServicesUSD 4 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Transfer of shared services positions from Marlborough to Costa Rica; 24 personnel terminated. Charge recorded in fiscal 2019.
2019-09-28restructuringcompleted2019-01-012019-12-31GlobalOtherUSD 3 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Other employee termination actions and facility closure costs in fiscal 2019. Includes $1.2M facility closure and $1.4M other charges.
2019-09-28restructuringin_progressUSD 6,600,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-06-29restructuringin_progress24United States (Marlborough, Massachusetts) and Costa RicaShared servicesUSD 3 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Company decided during the first nine months of fiscal 2019 to move certain shared services positions from Marlborough to its Costa Rica facility, terminating approximately 24 personnel plus other termination actions; $3.4M of restructuring expense recorded in the nine months ($1.0M, $1.3M and $1.1M in Q1, Q2 and Q3), with roughly $0.5M of additional charges expected in future quarters. Announcement date not specified; count is approximate per filer.
2019-06-29restructuringcompletedBelgium, France, Italy, Spain and Germany to Manchester, United KingdomInternational accounting and customer service organizationsUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Consolidation of legacy international accounting and customer service roles into Manchester, UK, decided in fiscal 2018; transition completed and employees terminated in the first quarter of fiscal 2019 (quarter ended December 29, 2018). $2.2M severance recorded in fiscal 2018 plus $1.0M of additional pro-rata charges in fiscal 2019. Affected-employee count not disclosed.
2019-06-29plant_closurecompletedHicksville, New York, United StatesMedical Aesthetics (Cynosure) manufacturingUSD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Closure of the facility manufacturing certain Cynosure products, decided in the third quarter of fiscal 2018; primarily manufacturing employees terminated after a required service period. Action completed January 2019, with $0.5M of severance recorded in fiscal 2018 and an additional $0.3M in the first quarter of fiscal 2019. Affected-employee count not disclosed.
2019-06-29acquisition_additioncompleted2018-07-31United States (Tucson, Arizona)Breast Healthbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Faxitron Bioptics, LLC completed July 31, 2018 for an $89.5M purchase price; purchase price allocation still preliminary. Headcount added not disclosed. Completion date falls just before the fiscal 2019 reporting period.
2019-06-29acquisition_additioncompleted2018-10-01United States (California)Breast Healthbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Focal Therapeutics, Inc. completed October 1, 2018 for a $120.1M purchase price; purchase price allocation still preliminary. Headcount added not disclosed.
2019-06-29acquisition_additionannounced2019-06-202019-12-31France (Aix-en-Provence)Ultrasound medical imaging (reportable segment not specified)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Exclusive negotiations to acquire SuperSonic Imagine announced June 20, 2019 (within the quarter) for aggregate cash payments of approximately $85M including payoff of SSI debt; structure contemplates acquiring about 46% of shares in August 2019 followed by a cash tender offer expected to close by end of calendar 2019. Headcount not disclosed.
2019-06-29restructuringin_progress242019-01-01United StatesShared ServicesUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Transfer of shared services positions from Marlborough to Costa Rica; termination of approx. 24 personnel. Q1 charge $1.0M.
2019-06-29restructuringin_progress2019-01-01United StatesShared ServicesUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Continuation of shared services transfer; Q2 charge $1.3M.
2019-06-29restructuringin_progress2019-01-01United StatesShared ServicesUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Continuation of shared services transfer; Q3 charge $1.1M.
2019-06-29restructuringcompleted2018-01-012019-03-31InternationalAccounting and Customer ServiceUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Consolidation of legacy international accounting and customer service into Manchester, UK. Transition completed in Q1 FY2019. Additional $1.0M recorded in FY2019 for remaining pro-rata charges.
2019-06-29plant_closurecompleted2018-01-012019-01-31United StatesManufacturingUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Closure of Hicksville, NY facility. Action completed in Jan 2019. Additional $0.3M recorded in Q1 FY2019 for remaining pro-rata charges.
2019-06-29restructuringin_progress2017-01-01United StatesCorporateUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Bedford, MA facility closure. Additional lease obligation charge of $1.4M recorded in Q3 FY2019 due to updated subletting assumptions.
2019-06-29restructuringin_progressUSD 2,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-30restructuringin_progress24Marlborough, Massachusetts to Costa RicaShared servicesUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Decisions made during the first and second quarters of fiscal 2019; no specific announcement date given. Approximately 24 personnel terminated plus other actions; $1.0M charged in Q1 and $1.3M in Q2. Company expects roughly $0.9M of additional charges in future quarters during the transition.
2019-03-30plant_closurecompleted2019-01-31Hicksville, New York, United StatesMedical Aesthetics (Cynosure manufacturing)USD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Closure decision made in fiscal 2018 Q3 (no exact date disclosed); employees, primarily manufacturing, notified in fiscal 2018 with charges recorded ratably over required service period. $0.5M severance recorded in fiscal 2018 plus $0.3M pro-rata charge in fiscal 2019 Q1; action completed January 2019. Headcount affected not disclosed.
2019-03-30restructuringcompleted2018-12-29Belgium, France, Italy, Spain, Germany (consolidated to Manchester, United Kingdom)International accounting and customer service organizationsUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Decision and plan finalized in fiscal 2018 ($2.2M severance recorded then); transition completed and employees terminated in the first quarter of fiscal 2019, with an additional $0.8M of pro-rata charges recorded in fiscal 2019. Number of positions eliminated not disclosed.
2019-03-30acquisition_additioncompleted2018-10-012018-10-01United States (California)Breast Healthbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Focal Therapeutics completed October 1, 2018 for $120.1M purchase price; acquired headcount not disclosed in the filing.
2019-03-30restructuringin_progress242019-01-01United StatesShared ServicesUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fiscal 2019 Actions: Transfer of shared services positions from Marlborough to Costa Rica; termination of approx. 24 personnel. Q2 charge of $1.3M recorded.
2019-03-30restructuringcompleted2018-01-012019-01-31InternationalAccounting and Customer ServiceUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fiscal 2018 Actions: Consolidation of legacy international accounting and customer service into Manchester, UK. Transition completed in Q1 FY2019. Additional $0.8M pro-rata charge recorded in FY2019.
2019-03-30plant_closurecompleted2018-01-012019-01-31United StatesManufacturingUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fiscal 2018 Actions: Closure of Hicksville, NY facility. Action completed in Jan 2019. Additional $0.3M pro-rata charge recorded in Q1 FY2019.
2019-03-30restructuringin_progressUSD 1,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-12-29restructuringin_progressCorporate initiatives and multiple business lines (integration activities)USD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Fiscal 2019 action: severance and benefits charges of $1.0 million recorded in Q1 FY2019 for employee terminations related to integration activities and corporate initiatives; no headcount affected disclosed. Accrued restructuring balance for fiscal 2019 actions was $0.3 million at quarter end.
2018-12-29restructuringcompletedBelgium, France, Italy, Spain, Germany (consolidated to Manchester, UK)International accounting and customer service organizationsUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Fiscal 2018 program: legacy international accounting and customer service roles consolidated into Manchester, UK. Transition completed in Q1 FY2019 and affected employees were terminated; an additional $0.6 million of pro-rata severance charges recorded in the quarter. No employee count disclosed.
2018-12-29plant_closurecompletedHicksville, New York, United StatesManufacturing (certain Cynosure products)USD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Closure decided in fiscal 2018 Q3; primarily manufacturing employees notified in fiscal 2018. An additional $0.3 million of pro-rata severance recorded in Q1 FY2019 and the action was completed in January 2019. No employee count disclosed.
2018-12-29acquisition_additioncompleted2018-10-012018-10-01California, United StatesBreast Healthbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Focal Therapeutics, Inc. completed October 1, 2018 for an initial purchase price of approximately $120.1 million (including $14.0 million holdbacks). No acquired headcount disclosed.
2018-12-29restructuringin_progress2018-10-01Multiple business linesIntegration activities and corporate initiativesUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fiscal 2019 Actions: Termination of certain employees primarily related to integration activities. Recorded $1.0 million in severance and benefits charges.
2018-12-29restructuringcompleted2017-10-012019-01-01Belgium, France, Italy, Spain, GermanyInternational accounting and customer serviceUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fiscal 2018 Actions: Consolidation of legacy international accounting and customer service organizations into Manchester, UK. Transition completed in Q1 FY2019. Additional $0.6 million recorded for remaining pro-rata charges.
2018-12-29plant_closurecompleted2018-07-012019-01-01Hicksville, New YorkManufacturing (Cynosure products)USD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fiscal 2018 Actions: Closure of Hicksville facility. Action completed in January 2019. Additional $0.3 million recorded for remaining pro-rata charges.
2018-12-29plant_closurecompleted2018-07-012018-12-29Westford, MassachusettsWarehouseUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fiscal 2018 Actions: Cease use of warehouse space. Termination agreement executed in Q1 FY2019 resulting in a $0.2 million benefit.
2018-12-29acquisition_additioncompleted2018-07-31Tucson, ArizonaBreast Healthbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Faxitron Bioptics, LLC. Headcount not explicitly quantified, but increased headcount and related expenses noted in MD&A.
2018-12-29acquisition_additioncompleted2018-10-01CaliforniaBreast Healthbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Focal Therapeutics, Inc. Headcount not explicitly quantified, but increased headcount and related expenses noted in MD&A.
2018-12-29restructuringin_progressUSD 1,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-29restructuringin_progressUnited StatesDiagnostics and Medical Aesthetics (primarily sales and marketing), plus a corporate executiveUSD 9 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Terminations across the first three quarters of fiscal 2018; charge includes $1.3M for equity award modification. Employee counts not disclosed. Announcement dates not specified.
2018-09-29restructuringin_progress2018-12-31Belgium, France, Italy, Spain, Germany (consolidation into Manchester, UK)International accounting and customer service organizationsUSD 2 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Plan finalized during fiscal 2018; transition expected to complete in the first quarter of fiscal 2019, with an additional $0.6M expected in Q1 fiscal 2019. Employee counts not disclosed.
2018-09-29plant_closurein_progress2018-12-31Hicksville, New York, United StatesMedical Aesthetics (Cynosure product manufacturing)USD 1 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Facility closure decided in Q3 fiscal 2018; primarily manufacturing employees notified, charges recognized ratably through Q1 fiscal 2019 with an additional $0.3M expected. Employee counts not disclosed.
2018-09-29acquisition_additioncompleted2017-12-112017-12-11Spain and PortugalBreast Health and Skeletal Health distributionbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Distributor acquisition; acquired headcount not disclosed.
2018-09-29acquisition_additioncompleted2018-07-312018-07-31Tucson, Arizona, United StatesBreast Healthbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Digital radiography systems developer acquired for $89.0M; acquired headcount not disclosed.
2018-09-29acquisition_additionannounced2018-10-012018-10-01California, United StatesBreast Healthsubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Closed one day after fiscal year-end for approximately $125.0M; acquired headcount not disclosed.
2018-09-29restructuringin_progress2018-01-012019-03-31Belgium, France, Italy, Spain, GermanyInternational accounting and customer serviceUSD 14 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Consolidation of legacy international accounting and customer service organizations into Manchester, UK. Transition expected to complete in Q1 FY2019. Total FY2018 charges were $14.2 million.
2018-09-29restructuringin_progress2018-01-012019-03-31United StatesDiagnostics and Medical Aestheticsrestructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Elimination of certain sales and marketing personnel in Diagnostics and Medical Aesthetics divisions. Included in total FY2018 charges of $14.2 million.
2018-09-29plant_closurein_progress2018-07-012019-03-31Hicksville, New YorkMedical Aesthetics (Cynosure)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Closure of Hicksville, NY facility manufacturing Cynosure products. Employees notified in Q3 FY2018. Included in total FY2018 charges of $14.2 million.
2018-09-29restructuringin_progressUSD 14,200,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-06-30restructuringin_progressGlobalCorporate; Diagnostics; Medical Aesthetics (sales and marketing personnel)USD 9 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Fiscal 2018 actions: terminations across the organization including a corporate executive; severance and benefits charges of $3.8M, $1.8M and $2.3M recorded in Q1, Q2 and Q3 respectively (Q1 amount includes $1.3M equity award modification). No employee counts disclosed.
2018-06-30restructuringin_progress2018-12-31Belgium, France, Italy, Spain, Germany (consolidation into Manchester, UK)International accounting and customer service organizationsUSD 3 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan finalized in Q3 FY2018 to consolidate legacy international accounting and customer service into Manchester, UK; estimated total severance and benefits charge approximately $3.0M, with $0.8M recorded in Q3. Transition expected through Q1 FY2019. Headcount not disclosed.
2018-06-30plant_closurein_progressHicksville, New York, United StatesMedical Aesthetics (Cynosure manufacturing)USD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Closure announced in Q3 FY2018; manufacturing of certain Cynosure products to be transferred to existing facilities. Employees notified in Q3; severance recorded ratably over required service period, $0.2M recorded in Q3. Headcount not disclosed.
2018-06-30acquisition_additioncompleted2017-12-112017-12-11Spain and PortugalBreast and Skeletal Health distribution (Emsor S.A.)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Emsor S.A. distributor completed 2017-12-11 for $16.3M purchase price; acquired headcount not disclosed.
2018-06-30acquisition_additionannounced2018-07-312018-07-31Tucson, Arizona, United StatesDigital radiography systems (Faxitron Bioptics, LLC)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Subsequent-event acquisition of Bioptics, Inc. / Faxitron completed 2018-07-31 for approximately $85.0M initial purchase price; ASC 805 disclosures deemed impractical at filing. Headcount not disclosed.
2018-06-30restructuringin_progress2018-04-01GlobalDiagnostics, Medical AestheticsUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q1 FY2018: Terminated certain employees across organization, including corporate executive and primarily sales/marketing personnel in Diagnostics and Medical Aesthetics segments.
2018-06-30restructuringin_progress2018-04-01GlobalDiagnostics, Medical AestheticsUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q2 FY2018: Terminated certain employees across organization, including corporate executive and primarily sales/marketing personnel in Diagnostics and Medical Aesthetics segments.
2018-06-30restructuringin_progress2018-04-01GlobalDiagnostics, Medical AestheticsUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q3 FY2018: Terminated certain employees across organization, including corporate executive and primarily sales/marketing personnel in Diagnostics and Medical Aesthetics segments.
2018-06-30restructuringin_progress2018-04-012019-03-31Belgium, France, Italy, Spain, GermanyAccounting, Customer ServiceUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q3 FY2018: Consolidating legacy international accounting and customer service organizations into Manchester, UK location. Eliminating positions in Belgium, France, Italy, Spain, and Germany. Transition expected through Q1 FY2019.
2018-06-30plant_closurein_progress2018-04-01Hicksville, New YorkManufacturingUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q3 FY2018: Closure of Hicksville, NY facility manufacturing certain Cynosure products. Manufacturing transferred to existing facilities. Terminating certain employees, primarily in manufacturing.
2018-06-30plant_closurein_progress2018-04-01Westford, MassachusettsWarehouseUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q3 FY2018: Ceased use of warehouse space on Lyberty Way. Recorded lease obligation charge.
2018-06-30restructuringin_progressUSD 5,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progressNot specifiedDiagnostics and Medical Aesthetics; primarily sales and marketing personnel, plus a corporate executiveUSD 6 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		FY2018 YTD severance and benefits charges of $3.8M in Q1 (incl. $1.3M equity award modification) and $1.8M in Q2; no employee count or completion date disclosed. Accrued restructuring balance of $1.3M for FY2018 actions at 2018-03-31.
2018-03-31acquisition_additioncompleted2017-12-112017-12-11Spain and PortugalBreast and Skeletal Health distribution (Emsor, S.A.)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Purchase price $15.4M; acquired distributor of Breast and Skeletal Health products. No headcount added disclosed.
2018-03-31restructuringin_progress2018-01-01GlobalDiagnostics, Medical AestheticsUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q2 2018 charges of $1.8M for severance benefits related to employees within Medical Aesthetics segment.
2018-03-31restructuringin_progress2017-10-01GlobalDiagnostics, Medical AestheticsUSD 6 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD 2018 charges of $5.6M for severance benefits primarily related to departure of an executive officer and employees within Diagnostics and Medical Aesthetics segments.
2018-03-31restructuringin_progressUSD 1,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-12-30restructuringin_progressUnited StatesCorporate; Diagnostics; Medical AestheticsUSD 4 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Terminations of certain employees including a corporate executive and sales/marketing staff; includes $1.3M equity award modification. No headcount disclosed.
2017-12-30restructuringin_progressUnited StatesMedical Aesthetics (Cynosure)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing Cynosure-related executive/employee terminations initiated in connection with the acquisition; $5.2M accrual remaining at quarter end. No headcount disclosed.
2017-12-30plant_closurein_progressBedford, Massachusetts, United StatesSkeletal Healthrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Bedford facility closure; $3.2M lease obligation accrual remaining. Facility not fully vacated; no additional cease-use charges recorded. No headcount disclosed.
2017-12-30acquisition_additioncompleted2017-12-112017-12-11Spain; PortugalBreast and Skeletal Health distributionbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of distributor Emsor S.A. for ~$13.1M; no headcount disclosed.
2017-12-30acquisition_additioncompleted2017-04-072017-04-07Germany; Austria; SwitzerlandBreast and Skeletal Health distributionbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of distributor MMS Medicor Medical Supplies GmbH for ~$19.0M; no headcount disclosed. Prior fiscal period but disclosed in this filing.
2017-12-30restructuringin_progress2018-01-01Diagnostics, Medical AestheticsUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fiscal 2018 Actions: Termination of certain employees across the organization, including a corporate executive and sales and marketing personnel. Charge includes $1.3 million related to modification of equity awards.
2017-12-30acquisition_additioncompleted2017-12-11Spain, PortugalBreast Health, Skeletal Healthbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Emsor S.A., a distributor of Breast and Skeletal Health products. Headcount not explicitly disclosed.
2017-12-30acquisition_additioncompleted2017-04-07Germany, Austria, SwitzerlandBreast Health, Skeletal Healthbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Medicor Medical Supply, a distributor of Breast and Skeletal Health products. Headcount not explicitly disclosed.
2017-12-30restructuringin_progressUSD 3,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-09-30divestiture_reductioncompleted2016-12-142017-01-31United StatesDiagnostics — blood screening businessdiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Blood screening business sold to Grifols for $1.85 billion; closed 2017-01-31. Headcount removed not disclosed. Hologic retained transition/contract-manufacturing roles supporting Grifols.
2017-09-30acquisition_additioncompleted2017-02-142017-03-22United StatesMedical Aestheticsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquired for $1.66 billion in cash; created the Medical Aesthetics reportable segment. Employees added not disclosed.
2017-09-30acquisition_additioncompleted2017-04-072017-04-07Germany, Austria, SwitzerlandBreast Health and Skeletal Health distributionbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Purchase price approximately $19.0 million. Employees added not disclosed.
2017-09-30restructuringcompletedUnited StatesMedical Aesthetics (Cynosure) — executive and employee terminationsUSD 7 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance recorded in three tranches: $1.5M in Q2, $4.3M in Q3 and $1.3M in Q4 of fiscal 2017 following the Cynosure acquisition. Headcount affected not disclosed. Fiscal 2017 total workforce-reduction charges were $8.5M.
2017-09-30restructuringcompletedUnited StatesBreast Health research and development; Diagnostics manufacturingUSD 1 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		One-time termination benefits recorded in Q4 fiscal 2017 for R&D headcount reductions in Breast Health and manufacturing position eliminations primarily in Diagnostics. Headcount affected not disclosed.
2017-09-30plant_closurein_progressBedford, Massachusetts, United StatesSkeletal Health manufacturingUSD 5 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Multi-year program initiated in fiscal 2015; Skeletal Health production outsourced to a third party. Fiscal 2017 activity comprises $3.5M (Q1) and $1.3M (Q3) lease obligation charges for vacated space. Facility not fully vacated at year-end, so cease-use criteria not yet met for the remainder. Employees affected not disclosed.
2017-09-30restructuringcompleted2017-03-22GlobalMedical Aesthetics (Cynosure)USD 13 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Aggregate charges of $13.3 million recorded in fiscal 2017. Includes severance and benefits primarily related to termination of Cynosure executives and employees, and lease obligation charges for vacated section of Bedford facility. Specific employee count not disclosed.
2017-09-30restructuringcompleted2017-09-25United StatesBreast Health, Diagnosticsrestructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Reduction in headcount in R&D within Breast Health and elimination of certain manufacturing personnel primarily in Diagnostics. Charge of $1.4 million recorded in Q4 2017. Specific employee count not disclosed.
2017-09-30restructuringin_progressUSD 2,500,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-07-01restructuringcompleted2017-03-22Medical Aesthetics (Cynosure) executive teamUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Termination of certain Cynosure executives following the acquisition; severance and benefits charge recorded in Q2 FY2017. No employee count disclosed.
2017-07-01restructuringin_progress2017-05-01Medical Aesthetics (Cynosure) executive teamUSD 4 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 FY2017 decision to terminate additional Cynosure executive team members; no employee count disclosed. Filer notes additional terminations may occur but no formal plan exists.
2017-07-01plant_closurein_progress2015-07-012016-12-31United States (Bedford, Massachusetts)Skeletal Health manufacturing / Breast Health supportUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Bedford facility closure; Q3 FY2017 incremental lease obligation charge of $1.3M from updated subtenant timing assumptions (plus $3.5M recorded in Q1 FY2017). Prior workforce reductions under this plan were completed in FY2016; no current-period employee count disclosed.
2017-07-01acquisition_additioncompleted2017-03-222017-03-22United States (Westford, Massachusetts)Medical Aestheticsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Cynosure completed 2017-03-22 for $1.658B total purchase price; headcount added not disclosed. Cynosure contributed $126.0M revenue and a $51.4M pre-tax loss from acquisition date through 2017-07-01.
2017-07-01acquisition_additioncompleted2017-04-072017-04-07Germany, Austria, SwitzerlandBreast Health / Skeletal Health distributionbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of MMS Medicor Medical Supplies GmbH for approximately $19.0M; headcount added not disclosed.
2017-07-01divestiture_reductioncompleted2016-12-142017-01-31Diagnostics (blood screening business)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of blood screening business to Grifols completed 2017-01-31 for $1.865B; headcount removed not disclosed. Hologic retained transition-services and contract-manufacturing roles for two to three years.
2017-07-01restructuringin_progress2017-04-01United StatesExecutiveUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Termination of certain Cynosure executives in Q2 FY2017.
2017-07-01restructuringin_progress2017-07-01United StatesExecutiveUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Termination of additional members of the executive team in Q3 FY2017.
2017-07-01restructuringin_progress2016-10-01United StatesManufacturingUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Lease obligation charges for vacated section of Bedford facility recorded in Q1 FY2017.
2017-07-01restructuringin_progress2017-07-01United StatesManufacturingUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Additional lease obligation charge for Bedford facility due to updated subtenant assumptions in Q3 FY2017.
2017-07-01restructuringcompleted2016-01-012016-12-31InternationalSales & MarketingUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance charges for international sales and marketing consolidation plan recorded in Q3 FY2016.
2017-07-01restructuringin_progressUSD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-04-01acquisition_additioncompleted2017-03-222017-03-22United StatesMedical Aestheticsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Cynosure completed March 22, 2017 for $1.66 billion; no headcount added disclosed. Approximately $18.5 million of transaction costs expensed in G&A.
2017-04-01restructuringcompleted3United StatesMedical AestheticsUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Three Cynosure executives terminated in connection with the acquisition; severance and benefits recorded under ASC 712/ASC 420. Additional terminations possible but no formal plan.
2017-04-01plant_closurein_progressBedford, Massachusetts, United StatesSkeletal Health manufacturing / Breast Health support servicesUSD 4 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Lease obligation charge for a vacated section of the Bedford facility recorded in Q1 fiscal 2017 (within the YTD period); no employee count disclosed. Transition substantially complete by end of calendar 2016; facility not fully vacated.
2017-04-01divestiture_reductioncompleted2016-12-142017-01-31Diagnostics — blood screening businessother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of blood screening business to Grifols completed January 31, 2017 for $1.865 billion; no headcount removed disclosed. Transition services to be provided over two to three years.
2017-04-01acquisition_additioncompleted2017-04-072017-04-07Germany, Austria, SwitzerlandBreast and Skeletal Health distributionsubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of MMS Medicor Medical Supplies GmbH completed April 7, 2017 for approximately $19.1 million; no headcount disclosed. Initial purchase accounting not yet complete.
2017-04-01restructuringcompleted2017-03-22GlobalMedical Aesthetics (Cynosure)USD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Termination of three Cynosure executives in connection with acquisition. Employee count not disclosed.
2017-04-01plant_closurein_progress2015-09-01Bedford, MassachusettsSkeletal Health / Breast HealthUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Lease obligation charges for vacated section of Bedford facility. Original workforce reduction occurred in prior fiscal years; current charge relates to lease cease-use criteria.
2017-04-01acquisition_additioncompleted2017-03-22GlobalMedical Aestheticsbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Cynosure, Inc. Headcount added not explicitly disclosed.
2017-04-01acquisition_additioncompleted2017-04-07Germany, Austria, SwitzerlandBreast and Skeletal Healthsubsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of MMS Medicor Medical Supplies GmbH. Headcount added not explicitly disclosed.
2017-04-01restructuringin_progressUSD 1,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-12-31plant_closurein_progress2015-06-302016-12-31Bedford, Massachusetts, United StatesSkeletal Health manufacturing; Breast Health support manufacturingUSD 4 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Bedford facility shutdown; Q1 FY2017 charge of $3.5M for lease obligations on a vacated section meeting cease-use criteria. Skeletal Health manufacturing outsourced; transition substantially completed by end of calendar 2016. Additional charges expected in FY2017 as further sections are vacated. No employee count disclosed.
2016-12-31restructuringin_progress2015-12-31InternationalInternational sales and marketing, field services, and support functionsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Consolidation of international sales/marketing and field services operations begun in Q1 FY2016; employees terminated each quarter of FY2016. No headcount disclosed; no FY2017 charges identified separately for this action.
2016-12-31restructuringcompleted2016-06-302016-09-24United StatesDiagnosticsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cost reduction initiative in part of the Diagnostics segment initiated in Q4 FY2016; employees notified and severance recorded under ASC 420. Action reported complete with no additional charges expected. No employee count disclosed.
2016-12-31divestiture_reductioncompleted2016-12-142017-01-31GlobalBlood screening business (within Diagnostics / molecular diagnostics)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of blood screening business to Grifols for $1.85B announced 2016-12-14; closed 2017-01-31 (subsequent event). Not classified as discontinued operations. No headcount associated with the divested business disclosed.
2016-12-31restructuringin_progress2016-09-24United StatesDiagnosticUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fiscal 2016 Actions: Lease obligation charges for vacated section of Bedford facility. Employees terminated in prior periods; current charge relates to facility closure costs.
2016-12-31restructuringcompleted2016-09-24United StatesDiagnosticUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fiscal 2016 Actions: Severance adjustments related to prior workforce reductions in Diagnostic segment.
2016-12-31restructuringin_progressUSD 3,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-24restructuringin_progressNot specifiedDiagnosticsUSD 1 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cost reduction initiative decided in Q4 FY2016; majority of employees notified in Q4 FY2016. Headcount not disclosed. An additional $0.2 million of charges expected in fiscal 2017.
2016-09-24plant_closurecompletedBedford, Massachusetts, United StatesSkeletal Health manufacturing (with Breast Health support services)USD 2 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Closure decided in Q3 FY2015; affected employees notified in Q1 FY2016 and required to remain through the transition, with charges recorded ratably. Skeletal Health production outsourced to a third party; severance action complete. Separately, $8-12 million of lease obligation charges expected in fiscal 2017 for the vacated facility. Headcount not disclosed.
2016-09-24restructuringin_progressInternationalSales and marketing, field services and certain support functionsUSD 8 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Plan begun in Q1 FY2016 to consolidate international sales/marketing and field service operations; employees terminated in each quarter of fiscal 2016. Includes $0.4 million of stock-based compensation. Headcount not disclosed.
2016-09-24restructuringcompleted2016-01-012016-09-24InternationalSales and marketing, field services, support functionsUSD 8 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Consolidation of international sales, marketing, and field services. Charges recorded in fiscal 2016.
2016-09-24plant_closurecompleted2015-07-012016-09-24United States (Bedford, MA)Manufacturing (Skeletal Health, Breast Health)USD 2 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Shutdown of Bedford facility. Manufacturing outsourced or transferred. Severance charges recorded in fiscal 2016.
2016-09-24restructuringcompleted2016-10-012016-12-31United StatesDiagnosticsUSD 1 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Cost reduction initiative in Diagnostics segment. Employees notified in Q4 fiscal 2016.
2016-09-24restructuringin_progressUSD 2,900,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-06-25plant_closurein_progress2016-12-31Bedford, Massachusetts, United StatesSkeletal Health manufacturing; Breast Health support manufacturing servicesUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Bedford facility closure; Skeletal Health production outsourced and Breast Health services moved to Danbury, CT and Marlborough, MA. Employees notified in Q1 FY2016; charges recorded ratably over required service period. Severance and benefits charges of $1.4M recorded in the nine months ended June 25, 2016 ($0.5M in Q3); company estimates total charges of approximately $1.7M. Transition expected complete by end of calendar 2016. Number of employees affected not disclosed.
2016-06-25restructuringin_progressInternational (multiple countries)International sales and marketing, field services, and certain support functionsUSD 6 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan to consolidate and improve operational efficiency of international sales/marketing and field services operations; certain employees identified and terminated in Q1, Q2 and Q3 of fiscal 2016. Severance and benefit charges of $6.1M recorded in the nine months ended June 25, 2016 ($1.0M in Q3). Company states it is continuing to assess organizational structure and additional severance charges are expected in fiscal 2016. Number of employees affected not disclosed.
2016-06-25restructuringin_progress2015-09-272016-12-31United StatesSkeletal Health / Breast HealthUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Closure of Bedford, MA facility. Manufacturing outsourced; support functions moved to Danbury, CT and Marlborough, MA. Employees notified in Q1 FY2016. Total estimated charges approx $1.7M.
2016-06-25restructuringin_progress2016-01-01InternationalSales and Marketing / Field ServicesUSD 6 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Consolidation of international sales, marketing, and field services. Additional severance charges expected in FY2016.
2016-06-25restructuringin_progressUSD 1,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-03-26plant_closurein_progress2015-06-302016-12-31Bedford, Massachusetts, United StatesSkeletal Health manufacturing; Breast Health manufacturing supportUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Bedford facility closure decided in fiscal Q3 2015; Skeletal Health manufacturing outsourced and Breast Health services moved to Danbury and Marlborough. Employees notified in fiscal Q1 2016; charges recorded ratably over required service period. Charge shown is six months ended March 26, 2016 severance and benefits; total estimated severance approximately $1.7 million. No employee count disclosed.
2016-03-26restructuringin_progress2015-09-30InternationalInternational sales and marketing, field services, and support functionsUSD 5 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan to consolidate international sales/marketing and field service operations; certain employees identified and terminated in fiscal Q1 and Q2 2016. Charge shown is six months ended March 26, 2016 severance and benefits. Company states additional severance charges are expected in fiscal 2016; no employee count or completion date disclosed.
2016-03-26restructuringin_progress2015-09-262016-12-31United StatesSkeletal Health / Breast HealthUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Closure of Bedford, MA facility. Manufacturing outsourced; support functions moved to Danbury, CT and Marlborough, MA. Employees notified in Q1 FY2016. Total estimated severance $1.7 million. $0.9 million charged YTD.
2016-03-26restructuringin_progress2016-01-01InternationalSales and Marketing / Field ServicesUSD 5 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Consolidation of international sales, marketing, and field services. Employees terminated in Q1 and Q2 FY2016. $5.1 million charged YTD. Additional charges expected.
2016-03-26restructuringin_progressUSD 3,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-12-26plant_closurein_progress2016-09-24Bedford, Massachusetts, United StatesSkeletal Health manufacturing; Breast Health manufacturing support; R&D, sales/service support and administrative functionsUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Decision to close Bedford facility made in Q3 FY2015; employees notified in Q1 FY2016. $0.5M severance recorded in Q1 FY2016; total estimated severance and benefits approximately $1.7M. Skeletal Health manufacturing to be outsourced; Breast Health services moved to Danbury, CT and Marlborough, MA. No employee count disclosed.
2015-12-26restructuringin_progressInternationalInternational sales and marketing, field services, and certain support functionsUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Consolidation to improve operational efficiency of international operations; certain employees terminated in Q1 FY2016. Charges recorded under ASC 712 and ASC 420. Company continuing to assess organizational structure and expects additional severance charges in fiscal 2016. No employee count disclosed.
2015-12-26restructuringin_progress2015-06-302016-09-24United StatesSkeletal Health, Breast Health, R&D, Sales, Services, AdministrativeUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Closure of Bedford, MA facility. Manufacturing outsourced; support functions moved to Danbury, CT and Marlborough, MA. Employees notified in Q1 FY2016. Total estimated charges ~$1.7M; $0.5M recorded in Q1.
2015-12-26restructuringin_progress2015-12-262016-09-24InternationalSales, Marketing, Field Services, Support FunctionsUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Consolidation of international sales, marketing, and field services. Employees terminated in Q1 FY2016. Additional charges expected in FY2016.
2015-12-26restructuringin_progressUSD 2,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-26restructuringin_progressWorldwideExecutive management and international sales/marketing/field service operationsUSD 10 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2015 charges of $10.0M severance and benefits, including $4.1M stock-based compensation, for executive management changes and consolidation/closure of certain international offices; includes shutdown of China mammography manufacturing operation. Headcount not disclosed.
2015-09-26restructuringcompleted2015-09-26WorldwideCorporate and international officesUSD 8 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Continuation of FY2014 program into FY2015: $6.0M severance and benefits plus $2.0M facility closure costs (vacated office locations meeting cease-use criteria). Action completed in fiscal 2015. Headcount not disclosed.
2015-09-26restructuringcompleted2015-09-26United StatesDiagnostics operations consolidation (Madison, WI to San Diego, CA)USD 1 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2015 charges of $0.6M ($0.1M severance, $0.5M facility closure) under multi-year Gen-Probe integration program; action complete. Headcount not disclosed.
2015-09-26plant_closureannounced2015-06-282016-09-30United States — Bedford, MassachusettsSkeletal Health manufacturing; Breast Health manufacturing support; R&D, sales/service support and administrationUSD 3 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Decision made in Q3 FY2015 to close Bedford facility; Skeletal Health manufacturing outsourced and other operations moved to Danbury, CT and Marlborough, MA. Employees notified in Q1 FY2016; estimated severance benefits approximately $3.0M, recorded ratably over required service period through end of FY2016. Headcount not disclosed.
2015-09-26restructuringannounced2015-12-31InternationalInternational sales and marketing, field services and support functionssubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Second plan begun in Q1 FY2016 to consolidate international sales/marketing and field service operations; plan and severance benefits still being finalized as of filing date. Headcount and charge not yet quantified.
2015-09-26divestiture_reductioncompleted2015-06-30International (subsidiary subsequently liquidated)Breast Health — MRI breast coils product lineUSD 10 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Product line sold in Q4 FY2014; operations fully ceased in Q3 FY2015 and subsidiary deemed substantially liquidated, triggering a $9.6M write-off of cumulative translation adjustment. Headcount not disclosed.
2015-09-26restructuringcompleted2015-01-012015-09-26WorldwideVariousUSD 29 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Aggregate charges of $28.5 million recorded in fiscal 2015 for severance, benefits, and facility closure costs related to executive management changes and consolidation of operations.
2015-09-26plant_closureannounced2015-07-012016-09-25Bedford, MassachusettsSkeletal Health and Breast Health manufacturingUSD 3 (millions)subsequent_events
f5-10k / Qwen3.6-27B-Q8_0		Decision to shut down Bedford, MA facility announced in Q3 FY2015. Estimated severance benefits of $3.0 million. Transition expected to complete by end of fiscal 2016.
2015-09-26restructuringannounced2015-10-01InternationalSales, marketing, field services, and supportsubsequent_events
f5-10k / Qwen3.6-27B-Q8_0		Plan to consolidate international sales, marketing, and field services announced in Q1 FY2016. Severance benefits being estimated.
2015-09-26restructuringin_progressUSD 6,500,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-09-26restructuringin_progressRestructuring Charges [Member] / Two Thousand Fifteen [Member]USD 28,500,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-06-27restructuringin_progressWorldwideExecutive management and international officesUSD 4 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing executive management changes and consolidation/closure of certain international offices across Q1-Q3 FY2015; $3.7M YTD severance and benefits charges (includes $0.7M stock-based comp). No employee count disclosed.
2015-06-27restructuringcompleted2014-12-31United States (San Diego, CA; Madison, WI)DiagnosticsUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Gen-Probe-related Diagnostics consolidation; charges recorded through Q1 FY2015 per filing. $0.6M recorded in nine months ended June 27, 2015. No current-period employee count disclosed.
2015-06-27plant_closurein_progressInternational (two office locations)Corporate / international officesUSD 8 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Residual FY2014 restructuring program (severance and facility closure costs for two office locations) still generating charges in FY2015; $7.7M YTD. No employee count disclosed for current period.
2015-06-27divestiture_reductioncompleted2015-06-27International (subsidiary operations ceased)Breast Health — MRI breast coils product lineUSD 10 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		MRI breast coils product line sold in Q4 FY2014; operations ceased and subsidiary deemed substantially liquidated in Q3 FY2015, triggering a $9.6M write-off of cumulative translation adjustment. No headcount figure disclosed.
2015-06-27restructuringin_progressWorldwideExecutive management and international officesUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fiscal 2015 Actions: Executive management changes and consolidation of international offices. Includes $0.7M stock-based compensation.
2015-06-27restructuringin_progressWorldwideDiagnostics OperationsUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Consolidation of Diagnostics Operations: Facility closure costs and severance/benefits.
2015-06-27restructuringin_progressGermanyBreast Health (Hitec-Imaging)USD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Hitec-Imaging Organic Photoconductor Manufacturing Line Shut-down: Severance, benefits, and facility closure costs.
2015-06-27divestiture_reductioncompletedWorldwideBreast Health (MRI breast coils)USD 10 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Write-off of cumulative translation adjustment related to MRI breast coils subsidiary deemed substantially liquidated.
2015-06-27restructuringin_progressUSD 11,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-27restructuringin_progressGuarantor Subsidiaries [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-27restructuringin_progressNon-Guarantor Subsidiaries [Member]USD 1,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-27restructuringin_progressParent Company [Member]USD 10,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-27restructuringin_progressConsolidation, Eliminations [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-27restructuringin_progressRestructuring Charges [Member] / Fiscal 2015 Charges [Member]USD 21,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-28restructuringin_progressWorldwideExecutive management and international officesUSD 3 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Continued executive management changes and consolidation/closure of international offices in Q1 and Q2 FY2015; includes $0.1M stock-based compensation for accelerated equity awards. No employee count disclosed.
2015-03-28restructuringin_progressWorldwideDiagnostics (Gen-Probe integration)USD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Facility closure costs and severance recorded in six months ended March 28, 2015 for ongoing Diagnostics consolidation; no employee count disclosed for current period.
2015-03-28restructuringin_progressWorldwideFiscal 2014 Actions (prior-year program continuing into FY2015)USD 6 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance and facility closure charges recorded in six months ended March 28, 2015 related to prior-year cost reduction and management reorganization program; no employee count disclosed for current period.
2015-03-28plant_closurein_progressGermanyBreast Health — Hitec-Imaging organic photoconductor manufacturing lineUSD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance and facility closure costs recorded in FY2015 for the Hitec-Imaging line shutdown; approximately 95 employees were affected under the original FY2014 program. No current-period employee count disclosed.
2015-03-28restructuringin_progressWorldwideExecutive management and international officesUSD 3 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fiscal 2015 Actions: Executive management changes and consolidation of international offices. Charge includes $0.1M stock-based compensation.
2015-03-28restructuringin_progressWorldwideDiagnostics OperationsUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Consolidation of Diagnostics Operations: Facility closure costs and severance/benefits.
2015-03-28restructuringin_progressWorldwideOther Operating Cost ReductionsUSD 6 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Includes workforce reductions and facility closure costs.
2015-03-28restructuringin_progressGermanyBreast Health (Hitec-Imaging)USD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Hitec-Imaging organic photoconductor manufacturing line shut-down: Severance and facility closure costs.
2015-03-28restructuringin_progressUSD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-28restructuringin_progressGuarantor Subsidiaries [Member]USD 100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-28restructuringin_progressNon-Guarantor Subsidiaries [Member]USD 2,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-28restructuringin_progressParent Company [Member]USD -400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-28restructuringin_progressConsolidation, Eliminations [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-12-27restructuringin_progressWorldwideDiagnosticsUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 FY2015 charge of $0.5M ($0.1M workforce reductions, $0.4M facility closure costs) from consolidating Gen-Probe and legacy diagnostics operations; Madison, Wisconsin molecular diagnostics relocation completed in fiscal 2014. No employee counts disclosed.
2014-12-27restructuringin_progress2015-09-26WorldwideExecutive management and international officesUSD 3 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 FY2015 severance and benefit charges of $2.5M (includes $0.1M stock-based compensation for accelerated equity awards) from continued executive management changes and consolidation/closure of certain international offices. No employee counts disclosed.
2014-12-27restructuringin_progress2015-09-26WorldwideCorporate and international officesUSD 5 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 FY2015 charges of $4.7M ($4.5M workforce reductions, $0.2M facility closure) under the fiscal 2014 cost-reduction program; company expects about $1.8M of additional charges in the remainder of fiscal 2015. No employee counts disclosed.
2014-12-27plant_closurein_progressGermanyBreast Health — Hitec-Imaging organic photoconductor manufacturing lineUSD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 FY2015 charge of $0.3M for severance, benefits and facility closure costs related to the Hitec-Imaging production line shutdown; approximately 95 affected employees were referenced for the fiscal 2014 phase of this action, with total severance and related charges estimated at about $9.5M. A $3.1M building impairment was recorded in fiscal 2014, not this quarter.
2014-12-27restructuringin_progress2014-10-01WorldwideExecutive management and international officesUSD 3 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fiscal 2015 Actions: Executive management changes and consolidation of international offices. Charge includes $0.1M stock-based compensation.
2014-12-27restructuringin_progress2013-10-012015-09-26WorldwideExecutive management and international officesUSD 5 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fiscal 2014 Actions continued: Cost reduction initiative. Company expects to incur approx $1.8M additional charges in remainder of fiscal 2015.
2014-12-27plant_closurein_progress952013-07-01GermanyBreast Health (Hitec-Imaging)USD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Hitec-Imaging organic photoconductor manufacturing line shut-down. Total estimated charges approx $9.5M. 95 employees affected.
2014-12-27restructuringin_progress2012-08-01United StatesDiagnostics (Gen-Probe)USD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Consolidation of Diagnostics Operations: Streamlining product development, sales, marketing, G&A, and manufacturing resources.
2014-12-27restructuringin_progressGuarantor Subsidiaries [Member]USD 500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-12-27restructuringin_progressNon-Guarantor Subsidiaries [Member]USD 5,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-12-27restructuringin_progressConsolidation, Eliminations [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-12-27restructuringin_progressUSD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-12-27restructuringin_progressParent Company [Member]USD 1,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-27restructuringcompleted2013-12-28WorldwideCorporate / multiple functionsUSD 6 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		First-quarter fiscal 2014 cost reduction initiative involving headcount reductions worldwide; charge includes $0.4M of stock-based compensation. Announced during Q1 FY2014 (Oct–Dec 2013); headcount affected not disclosed.
2014-09-27othercompleted2013-12-062013-12-06United StatesExecutive management (President and CEO)USD 7 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Separation of prior President and CEO John W. Cumming upon appointment of Stephen P. MacMillan; charge includes $4.4M of accelerated stock-based compensation.
2014-09-27restructuringin_progress2015-09-27WorldwideExecutive management and corporate functions; includes consolidation and closure of certain international officesUSD 17 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance recorded across Q2–Q4 FY2014 for executive management changes and additional cost reductions; includes $1.8M stock-based compensation for award modifications. Approximately $5.0M of additional charges expected in fiscal 2015 as benefits are recognized ratably. Announced during FY2014 quarters; exact dates not disclosed.
2014-09-27plant_closurecompleted952014-09-27GermanyBreast Health — Hitec-Imaging organic photoconductor manufacturing lineUSD 9 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Shutdown decided in Q4 FY2013; approximately 95 employees terminated during FY2014 after works council negotiations. Total severance estimated at approximately $9.1M; a separate $3.1M non-cash building impairment was also recorded in Q1 FY2014.
2014-09-27plant_closurecompleted2014-03-29United States (Indianapolis, Indiana)Breast Health — interventional breast products transferred to Costa RicaUSD 0 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Transfer completed in Q1 FY2014 and all employees at the location terminated; FY2014 charges comprise $0.2M severance plus a $0.4M lease termination charge. Headcount affected not disclosed.
2014-09-27plant_closurecompleted2014-09-27United States (Madison, Wisconsin)Diagnostics — legacy molecular diagnostics operations transferred to San Diego, CaliforniaUSD 3 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Transfer finalized at the end of fiscal 2014 with many Madison employees terminated; charge recorded ratably over required service periods. Headcount affected not disclosed.
2014-09-27divestiture_reductioncompleted2014-09-27Not disclosedBreast Health — MRI breast coils product lineUSD 5 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale completed in Q4 FY2014 with a loss on disposal of $5.3M; transition manufacturing services provided to the buyer for six months. Headcount transferred or eliminated not disclosed.
2014-09-27divestiture_reductioncompleted2013-12-28Not disclosedDiagnostics — Elucigene product line assetsUSD 0 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of held-for-sale assets finalized in Q1 FY2014 for $2.8M, resulting in additional charges of $0.2M in fiscal 2014. Headcount affected not disclosed.
2014-09-27restructuringin_progress2014-09-27WorldwideCorporate / multiple functionsUSD 1 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance recorded in fiscal 2014 under the cost reduction initiative first implemented in fiscal 2013; charge relates to employees continuing service beyond the minimum retention period. Program announced in FY2013 — only the FY2014 charge is captured here.
2014-09-27restructuringcompleted2014-01-012014-09-27WorldwideVariousUSD 52 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Aggregate charges of $51.7 million recorded in fiscal 2014. Includes severance, benefits, impairment of buildings, and loss on divestiture. Specific employee counts not disclosed for the aggregate program.
2014-09-27restructuringcompleted952013-12-012014-09-27GermanyManufacturingUSD 9 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Termination of approximately 95 employees at Hitec-Imaging organic photoconductor manufacturing line. $8.7 million in severance charges recorded in fiscal 2014.
2014-09-27divestiture_reductioncompleted2014-06-012014-09-27WorldwideBreast HealthUSD 5 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Sale of MRI breast coils product line completed in Q4 2014. Loss on disposal of $5.3 million. Employee count not disclosed.
2014-09-27restructuringin_progressUSD 51,700,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-09-27restructuringin_progressRestructuring Charges [Member] / Year Two Thousand Fourteen [Member]USD 51,700,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-09-27restructuringin_progressGuarantor Subsidiaries [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-09-27restructuringin_progressNon-Guarantor Subsidiaries [Member]USD 26,300,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-09-27restructuringin_progressConsolidation, Eliminations [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-09-27restructuringin_progressParent Company [Member]USD 8,400,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-06-28plant_closurein_progress952013-06-30Warstein, GermanyBreast Health — Hitec-Imaging organic photoconductor manufacturing lineUSD 9 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Approximately 95 affected employees; Works Council negotiations completed in Q1 FY2014. Charges of $7.3M in Q2 and $1.1M in Q3 FY2014; additional charges expected in FY2014 and FY2015. A separate $3.1M building impairment was recorded in Q1 FY2014.
2014-06-28restructuringin_progress2013-09-29WorldwideCorporate — cost reduction initiative (headcount reductions and research project/operating cost review)USD 14 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance and benefit charges of $6.3M (Q1), $3.0M (Q2), and $5.0M (Q3) FY2014; Q3 charge includes $1.7M stock-based comp for equity award modifications. Employee counts not disclosed.
2014-06-28othercompleted2013-12-062013-12-06United StatesExecutive management — CEO transition (John W. Cumming separation)USD 7 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Separation benefits under employment letter dated 2013-07-18; includes $4.4M stock-based compensation for acceleration of all outstanding equity awards. Recorded in Q1 FY2014.
2014-06-28restructuringin_progress2013-09-292014-09-27Madison, Wisconsin to San Diego, CaliforniaDiagnostics — legacy molecular diagnostics operations consolidationUSD 7 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Total estimated severance and benefits of ~$7.1M recognized ratably over affected employees' service periods; $2.3M recorded in nine months ended 2014-06-28. Transfer expected to finalize by end of FY2014; many Madison employees already terminated. Headcount not disclosed.
2014-06-28plant_closurecompleted2012-06-302014-03-29Indianapolis, Indiana, United StatesBreast Health — interventional breast products transferred to Costa RicaUSD 6 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Transfer completed and employee terminations completed in Q1 FY2014; total severance and benefit charges of $5.9M. Action complete — no additional charges expected.
2014-06-28divestiture_reductioncompleted2013-06-302013-12-28Diagnostics — Elucigene product lineUSD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Assets designated held-for-sale in Q4 FY2013 with $0.7M fair-value charge; sale finalized for $2.8M in Q1 FY2014 with additional $0.2M charge. Headcount impact not disclosed.
2014-06-28restructuringin_progress2014-01-01WorldwideVarious (R&D, Sales, Marketing, G&A, Manufacturing)USD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fiscal 2014 Actions: Cost reduction initiative implemented in Q1 2014 involving headcount reductions and evaluation of research projects. Includes severance/benefits charges of $6.3M in Q1 and $3.0M in Q2/Q3. No specific employee count disclosed for this component.
2014-06-28restructuringin_progress2013-12-06United StatesExecutive ManagementUSD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Separation benefits for former CEO John W. Cumming upon appointment of Stephen P. MacMillan. Charge recorded in Q1 2014.
2014-06-28restructuringin_progress952013-10-012015-09-27GermanyManufacturing (Hitec-Imaging)USD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Shutdown of Hitec-Imaging organic photoconductor manufacturing line. Approximately 95 affected employees. Total estimated charges ~$9.2M. $7.3M recorded in Q2 2014, $1.1M in Q3 2014. Additional charges expected in FY2014 and FY2015.
2014-06-28restructuringcompleted2012-10-012014-03-31United StatesManufacturing (Breast Health)USD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Closure of Indianapolis Facility. Transfer of production to Costa Rica completed in Q1 2014. $0.2M severance recorded in Q1 2014. Action is complete.
2014-06-28restructuringin_progress2012-08-012014-09-27United StatesDiagnostics (Gen-Probe)USD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Consolidation of Diagnostics Operations. Transfer of molecular diagnostics from Madison, WI to San Diego, CA. $0.6M recorded in Q3 2014. Expected to finalize by end of FY2014.
2014-06-28restructuringin_progressUSD 6,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-28restructuringin_progressRestructuring Charges [Member] / Year Two Thousand Fourteen [Member]USD 36,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-28restructuringin_progressGuarantor Subsidiaries [Member]USD 15,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-28restructuringin_progressNon-Guarantor Subsidiaries [Member]USD 14,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-28restructuringin_progressConsolidation, Eliminations [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-28restructuringin_progressParent Company [Member]USD 7,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-29restructuringin_progress2013-09-29WorldwideMultipleUSD 6 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cost reduction initiative with worldwide headcount reductions; $6.3M severance charge in Q1 FY2014 including $0.4M stock-based comp. Additional $3.0M charge in Q2 FY2014 for terminated executives and employees.
2014-03-29plant_closurecompleted2012-06-302013-12-31United StatesBreast Healthrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Transfer of interventional breast product production from Indianapolis to Costa Rica completed in Q1 FY2014; employee terminations completed. Total severance and benefits charge under this action was $5.9M.
2014-03-29plant_closurein_progress952013-06-302015-09-30GermanyBreast HealthUSD 7 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Shutdown of Hitec-Imaging manufacturing line in Warstein, Germany. Approximately 95 affected employees; $7.3M severance charge recorded in Q2 FY2014. Total estimated severance and related charges approximately $9.1M, with additional charges expected in FY2014 and FY2015. Also includes $3.1M building impairment in Q1 FY2014.
2014-03-29restructuringin_progress2012-09-302014-09-27United StatesDiagnosticsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Transfer of legacy molecular diagnostics operations from Madison, Wisconsin to Gen-Probe facilities in San Diego, California. Expected to be finalized by end of FY2014. Total estimated severance and benefits charge approximately $7.3M, recorded ratably. $1.7M recorded in six months ended March 29, 2014.
2014-03-29restructuringin_progress2013-06-30WorldwideMultipleUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		FY2013 cost reduction initiative with worldwide headcount reductions; total charge was $5.4M. $0.9M recorded in six months ended March 29, 2014 for employees continuing beyond minimum retention period.
2014-03-29divestiture_reductioncompleted2013-06-302013-12-31DiagnosticsUSD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of Elucigene product line assets finalized in Q1 FY2014 for $2.8M, resulting in additional charges of $0.2M for the six months ended March 29, 2014.
2014-03-29othercompleted2013-12-062013-12-06United StatesExecutiveUSD 7 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		CEO transition: separation benefits for John W. Cumming upon appointment of Stephen P. MacMillan as President and CEO on December 6, 2013. Charge included $4.4M stock-based compensation for acceleration of all outstanding equity awards. Additional $0.2M recorded in Q2 FY2014.
2014-03-29restructuringin_progress2013-10-01WorldwideVarious (R&D, Sales, Marketing, G&A, Manufacturing)USD 12 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fiscal 2014 Actions: Cost reduction initiative implemented in Q1 FY2014 involving headcount reductions and evaluation of research projects. Includes termination of prior CEO John Cumming ($6.6M charge in Q1, $0.2M in Q2) and termination of certain executives/employees in Q2 ($3.0M charge). Charges recorded pursuant to ASC 420 and ASC 712.
2014-03-29restructuringin_progress952013-10-01GermanyManufacturing (Hitec-Imaging)USD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Hitec-Imaging Organic Photoconductor Manufacturing Line Shut-down: Termination of approximately 95 employees primarily in manufacturing. Negotiations with local Works Council completed in Q1 FY2014. $7.3M recorded in Q2 FY2014. Total estimated charge ~$9.1M.
2014-03-29restructuringcompleted2012-10-012014-03-29United States (Indianapolis)Manufacturing (Breast Health)USD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Closure of Indianapolis Facility: Transfer of interventional breast products production to Costa Rica completed in Q1 FY2014. Termination of employees completed. $0.2M severance recorded in Q1 FY2014. Action is complete.
2014-03-29restructuringin_progress2012-10-012014-09-27United States (Wisconsin to California)Diagnostics (Molecular Diagnostics)USD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Consolidation of Diagnostics Operations: Moving legacy molecular diagnostics from Madison, WI to San Diego, CA. Expected to finalize by end of FY2014. Many Madison employees to be terminated. $0.9M recorded in Q2 FY2014. Total estimated charge ~$7.3M.
2014-03-29restructuringin_progressUSD 29,909,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-29restructuringin_progressParent Company [Member]USD 6,646,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-29restructuringin_progressGuarantor Subsidiaries [Member]USD 12,087,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-29restructuringin_progressNon Guarantor Subsidiaries [Member]USD 11,176,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-29restructuringin_progressRestructuring Charges [Member] / Closure Of Interventional Breast Facility In Indianapolis [Member] / Year Two Thousand Fourteen [Member]restructuring_footnote
f5-10q / no-ai-xblr
2014-03-29restructuringin_progressRestructuring Charges [Member] / Restructuring Action Two Thousand Thirteen [Member] / Year Two Thousand Fourteen [Member]restructuring_footnote
f5-10q / no-ai-xblr
2014-03-29restructuringin_progressRestructuring Charges [Member] / Restructuring Action Two Thousand Fourteen [Member] / Year Two Thousand Fourteen [Member]restructuring_footnote
f5-10q / no-ai-xblr
2014-03-29restructuringin_progressRestructuring Charges [Member] / Other Operating Cost Reductions [Member] / Year Two Thousand Fourteen [Member]restructuring_footnote
f5-10q / no-ai-xblr
2014-03-29restructuringin_progressRestructuring Charges [Member] / Consolidation Of Diagnostics Operations [Member] / Year Two Thousand Fourteen [Member]restructuring_footnote
f5-10q / no-ai-xblr
2014-03-29restructuringin_progressRestructuring Charges [Member] / Year Two Thousand Fourteen [Member]USD 29,909,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-29restructuringin_progressConsolidation Eliminations [Member]restructuring_footnote
f5-10q / no-ai-xblr
2013-12-28restructuringin_progress2013-09-29WorldwideCompany-wideUSD 6 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cost reduction initiative involving worldwide headcount reductions; includes $0.4M stock compensation for accelerated Gen-Probe options. No employee count disclosed.
2013-12-28othercompleted12013-12-062013-12-06United StatesExecutive / CorporateUSD 7 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Separation of prior President/CEO John W. Cumming upon appointment of Stephen MacMillan; charge includes $4.4M stock compensation for accelerated equity awards.
2013-12-28plant_closurein_progress962013-06-302014-09-27GermanyOther Operating Cost Reductions — Hitec organic photoconductor manufacturing lineUSD 7 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Shutdown decided in Q4 FY2013; Works Council negotiations completed in Q1 FY2014. Employee notifications began Q2 FY2014. A $3.1M building impairment was recorded in Q1 FY2014. Announcement date reflects the quarter in which the shutdown decision was finalized.
2013-12-28plant_closurecompleted2012-06-302013-12-28United States — Indianapolis, IndianaBreast Health — interventional breast productsUSD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Transfer of production to Costa Rica completed in Q1 FY2014 and employee terminations completed. Q1 FY2014 charge of $0.2M severance plus $0.4M lease termination charges. Total program severance charge was $5.9M across all periods. Announcement date reflects original Q4 FY2012 decision.
2013-12-28restructuringin_progress2012-09-302014-09-27United States — Madison, Wisconsin to San Diego, CaliforniaDiagnostics — legacy molecular diagnostics operationsUSD 7 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Estimated total severance and benefits charge of $6.9M for the Madison facility relocation, recorded ratably over affected employees' service periods. $0.8M recorded in Q1 FY2014. Transfer expected to be finalized by end of fiscal 2014, at which point Madison employees will be terminated. No employee count disclosed.
2013-12-28divestiture_reductioncompleted2013-06-302013-12-28Diagnostics — Elucigene product lineUSD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of Elucigene assets finalized in Q1 FY2014 for $2.8M; additional $0.1M charge recorded. Assets designated held-for-sale in Q4 FY2013. No employee count disclosed.
2013-12-28restructuringin_progress2013-06-30WorldwideCompany-wide — Fiscal 2013 ActionsUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Continuing worldwide cost reduction initiative from FY2013; $0.7M severance and benefits charge recorded in Q1 FY2014. Total estimated program charge approximately $5.4M. No employee count disclosed.
2013-12-28restructuringin_progress2013-07-18WorldwideCorporate / ExecutiveUSD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Separation benefits for former CEO John W. Cumming upon appointment of Stephen MacMillan. Includes $4.4M stock compensation.
2013-12-28restructuringin_progress2013-10-01WorldwideVariousUSD 6 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fiscal 2014 cost reduction initiative: headcount reduction and evaluation of research projects. Includes $0.4M stock compensation.
2013-12-28plant_closurecompleted2012-10-012014-03-31Indianapolis, IndianaBreast HealthUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Transfer of interventional breast products production to Costa Rica completed. Charge relates to lease termination.
2013-12-28restructuringin_progress962013-10-012014-09-27GermanyManufacturingUSD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Shutdown of Hitec-Imaging organic photoconductor manufacturing line. Notifications began in Q2 FY2014.
2013-12-28restructuringin_progress2012-08-012014-09-27Madison, Wisconsin to San Diego, CaliforniaDiagnosticsUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Consolidation of legacy molecular diagnostics operations. $0.8M recorded in Q1 FY2014.
2013-12-28restructuringin_progressUSD 18,350,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-12-28restructuringin_progressParent Company [Member]USD 4,990,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-12-28restructuringin_progressConsolidation Eliminations [Member]restructuring_footnote
f5-10q / no-ai-xblr
2013-12-28restructuringin_progressGuarantor Subsidiaries [Member]USD 9,756,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-12-28restructuringin_progressNon Guarantor Subsidiaries [Member]USD 3,604,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-12-28restructuringin_progressRestructuring Charges [Member] / Closure Of Interventional Breast Facility In Indianapolis [Member] / Year Two Thousand Fourteen [Member]USD 683,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-12-28restructuringin_progressRestructuring Charges [Member] / Restructuring Action Two Thousand Thirteen [Member] / Year Two Thousand Fourteen [Member]USD 671,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-12-28restructuringin_progressRestructuring Charges [Member] / Restructuring Action Two Thousand Fourteen [Member] / Year Two Thousand Fourteen [Member]USD 12,933,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-12-28restructuringin_progressRestructuring Charges [Member] / Other Operating Cost Reductions [Member] / Year Two Thousand Fourteen [Member]USD 3,181,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-12-28restructuringin_progressRestructuring Charges [Member] / Consolidation Of Diagnostics Operations [Member] / Year Two Thousand Fourteen [Member]USD 796,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-12-28restructuringin_progressRestructuring Charges [Member] / Year Two Thousand Fourteen [Member]USD 18,350,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-12-28restructuringin_progress96Other Operating Cost Reductions [Member]restructuring_footnote
f5-10q / no-ai-xblr		Expected positions to be eliminated
2013-09-28restructuringin_progress2014-12-31United StatesDiagnosticsUSD 14 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Fiscal 2013 workforce-reduction charges for the Diagnostics consolidation begun in fiscal 2012: overlapping R&D, sales, marketing and G&A functions reduced, legacy molecular diagnostics operations moving from Madison, Wisconsin to San Diego, California (transfer expected to finalize by end of fiscal 2014). Includes $9.7M in Q2 FY2013 for acceleration of retention payments and equity awards for certain Gen-Probe executives, including former Chairman/CEO Carl Hull, and $6.3M of stock-based compensation. Employee counts not disclosed.
2013-09-28plant_closurein_progress2014-03-31United States — Indianapolis, IndianaBreast HealthUSD 6 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Closure of the Indianapolis facility and transfer of interventional breast product production to Costa Rica; transfer expected to complete in the first half of fiscal 2014 with the majority of on-site employees terminated. Fiscal 2013 charges comprise $4.8M severance, $0.2M facility closure and $0.7M other. Employee counts not disclosed.
2013-09-28restructuringcompleted2013-09-28WorldwideCompany-wideUSD 5 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Third-quarter fiscal 2013 cost reduction initiative comprising headcount reductions on a worldwide basis plus review of research projects and operating costs; estimated total severance and benefits charge approximately $5.2M, of which $4.6M was recorded in fiscal 2013. Employee counts not disclosed.
2013-09-28restructuringcompleted2013-07-182013-09-28WorldwideCompany-wideUSD 7 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Headcount reductions implemented in connection with the July 18, 2013 resignation of President/CEO Robert A. Cascella and appointment of John W. Cumming; all employees notified before September 28, 2013 and primarily ceased employment in the fourth quarter. Includes $1.4M of stock compensation from modified equity awards. Employee counts not disclosed.
2013-09-28plant_closurecompleted2013-09-28Germany — Hitec-Imaging, to Newark, Delaware, USABreast HealthUSD 1 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Consolidation of selenium panel coating production, transferring the line from the German Hitec-Imaging subsidiary to Newark, Delaware; transfer completed in the fourth quarter of fiscal 2013 with severance for primarily manufacturing personnel. Employee counts not disclosed.
2013-09-28plant_closureannounced2013-06-302014-09-27GermanyBreast Health — organic photoconductor manufacturingUSD 0 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Fourth-quarter fiscal 2013 decision to shut down the Hitec-Imaging organic photoconductor manufacturing line in Germany; approximately 100 employees expected to be terminated in fiscal 2014, subject to negotiation with the local Works Council. A $0.3M equipment impairment was recorded in fiscal 2013; severance to be recorded as incurred. Announcement date approximated to the fiscal fourth quarter.
2013-09-28divestiture_reductioncompleted2013-01-032013-03-22United StatesDiagnostics — LIFECODES transplant diagnostics businessbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of the LIFECODES business to Immucor, Inc. for $85.0M cash plus a contingent $10.0M; closed March 22, 2013 with a $0.9M gain recorded. Business had contributed $23.2M of revenue in fiscal 2013. Associated headcount not disclosed.
2013-09-28restructuringannounced2013-12-28WorldwideCompany-wideUSD 5 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Additional cost reduction initiative with headcount reductions implemented in the first quarter of fiscal 2014; all affected employees notified and ceased employment in that quarter. Expected severance and benefits charge of approximately $4.6M. Employee counts not disclosed.
2013-09-28restructuringin_progress2012-08-012014-09-28United StatesDiagnosticsUSD 13 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Consolidation of Diagnostics operations following Gen-Probe acquisition. Includes termination of certain employees in R&D, sales, marketing, and G&A. Majority ceased working in Q4 FY2012.
2013-09-28restructuringin_progress2012-08-012014-09-28United StatesDiagnosticsUSD 6 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Transfer of legacy molecular diagnostics operations from Madison, Wisconsin to San Diego, California. Estimated total charge of $6.4 million recorded ratably.
2013-09-28plant_closurein_progress2012-09-292014-03-29United StatesBreast HealthUSD 7 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Closure of Indianapolis facility and transfer of interventional breast products production to Costa Rica. All employees at location to be terminated.
2013-09-28restructuringin_progress2013-06-29WorldwideCorporateUSD 5 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Fiscal 2013 Actions: Cost reduction initiative comprised of reducing headcount and evaluating research projects. Terminated certain employees worldwide.
2013-09-28restructuringcompleted2013-07-182013-09-28United StatesCorporateUSD 7 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Management change: Resignation of CEO Robert A. Cascella and appointment of John W. Cumming. Additional headcount reductions implemented. All employees notified prior to Sept 28, 2013.
2013-09-28plant_closurein_progress1002013-09-282014-09-28GermanyBreast Healthrestructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Shutdown of Hitec-Imaging organic photoconductor manufacturing line. Approximately 100 employees to be terminated in FY2014. Working with Works Council.
2013-09-28restructuringcompleted2012-06-302013-09-28GermanyBreast HealthUSD 1 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Consolidation of Selenium panel coating production from Germany to Newark, Delaware. Terminated certain manufacturing personnel.
2013-09-28restructuringannounced2013-10-012014-03-29WorldwideCorporateUSD 5 (millions)subsequent_events
f5-10k / Qwen3.6-27B-Q8_0		Subsequent event: Additional cost reduction initiative implemented in Q1 FY2014. All affected employees notified and ceased employment in Q1 FY2014.
2013-09-28restructuringin_progressUSD 32,805,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-09-28restructuringin_progressParent Company [Member]USD 4,889,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-09-28restructuringin_progressConsolidation Eliminations [Member]restructuring_footnote
f5-10k / no-ai-xblr
2013-09-28restructuringin_progressGuarantor Subsidiaries [Member]USD 21,647,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-09-28restructuringin_progressNon Guarantor Subsidiaries [Member]USD 6,269,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-09-28restructuringin_progressRestructuring Charges [Member] / Closure Of Interventional Breast Facility In Indianapolis [Member] / Year Two Thousand Thirteen [Member]USD 5,629,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-09-28restructuringin_progressRestructuring Charges [Member] / Restructuring Action Two Thousand Thirteen [Member] / Year Two Thousand Thirteen [Member]USD 11,374,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-09-28restructuringin_progressRestructuring Charges [Member] / Other Operating Cost Reductions [Member] / Year Two Thousand Thirteen [Member]USD 1,740,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-09-28restructuringin_progressRestructuring Charges [Member] / Consolidation Of Diagnostics Operations [Member] / Year Two Thousand Thirteen [Member]USD 13,950,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-09-28restructuringin_progressRestructuring Charges [Member] / Year Two Thousand Thirteen [Member]USD 32,805,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-09-28restructuringin_progress100Facility Closing [Member]restructuring_footnote
f5-10k / no-ai-xblr		Expected positions to be eliminated
2013-06-29restructuringin_progress2012-10-012014-12-31United States (Madison, Wisconsin to San Diego, California)DiagnosticsUSD 13,385 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		FY2013 charges; includes $6.3M stock-based compensation. Transfer of legacy molecular diagnostics operations expected finalized by end of calendar 2014; total estimated severance/benefits charge ~$6.1M for the Madison move. No employee count disclosed.
2013-06-29plant_closurein_progress2012-07-012014-06-30United States (Indianapolis, Indiana to Costa Rica)Breast HealthUSD 5,156 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		FY2013 charges; transfer of interventional breast product production expected completed in first half of calendar 2014. Total estimated severance/benefits charge ~$6.2M. No employee count disclosed.
2013-06-29reduction_in_forcein_progress2013-05-01WorldwideAll segmentsUSD 3,609 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cost reduction initiative implemented in Q3 FY2013 due to operating results below expectations; $3.6M of severance and benefit charges recorded in the quarter; total estimated charge ~$4.4M based on actions taken to date. Additional headcount reductions may occur in Q4 FY2013 but not expected to be material. No employee count disclosed.
2013-06-29restructuringin_progress2013-01-012013-09-28Germany to United States (Newark, Delaware)Breast HealthUSD 1,490 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Termination communications began January 2013; primarily manufacturing personnel. Transfer expected completed in fiscal 2013. No employee count disclosed.
2013-06-29acquisition_additioncompleted2012-12-312012-12-31ChinaBreast Healthbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of certain assets for net purchase price of $4.4M including contingent consideration; distributor of Breast Health products in China. No headcount disclosed.
2013-06-29acquisition_additioncompleted2013-05-312013-05-31United StatesBreast Healthbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of assets related to the Contura brachytherapy device for net purchase price of $2.4M, resolving C.R. Bard patent litigation. No headcount disclosed.
2013-06-29divestiture_reductioncompleted2013-01-032013-03-22United StatesDiagnosticsother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of LIFECODES business to Immucor for $85.0M plus contingent $10.0M; closed March 22, 2013 with $0.9M gain. No headcount removed disclosed.
2013-06-29restructuringin_progress2013-04-01WorldwideVarious (R&D, Sales, Marketing, G&A)USD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fiscal 2013 Action: Cost reduction initiative implemented in Q3 2013 due to operating results not meeting expectations. Terminated certain employees worldwide. Estimated total severance charge approx $4.4 million; $3.6 million recorded in Q3.
2013-06-29restructuringin_progress2012-10-012014-12-31United States (Madison, WI to San Diego, CA)DiagnosticsUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Consolidation of Diagnostics Operations: Transfer of legacy molecular diagnostics operations from Madison, WI to San Diego, CA. Expected to finalize by end of calendar 2014. $0.8 million recorded in Q3 2013.
2013-06-29restructuringin_progress2012-10-012014-06-30United States (Indianapolis, IN to Costa Rica)Breast HealthUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Closure of Indianapolis Facility: Transfer of interventional breast products production to Costa Rica. Expected completion in first half of calendar 2014. $1.4 million recorded in Q3 2013.
2013-06-29restructuringin_progress2012-07-012013-09-30Germany to United States (Newark, DE)Breast HealthUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Consolidation of Selenium Panel Coating Production: Transfer from Hitec-Imaging German subsidiary to Newark, DE. Expected completion in fiscal 2013. $0.4 million recorded in Q3 2013.
2013-06-29restructuringin_progressUSD 23,085,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-29restructuringin_progressParent Company [Member]USD 948,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-29restructuringin_progressGuarantor Subsidiaries [Member]USD 17,632,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-29restructuringin_progressNon Guarantor Subsidiaries [Member]USD 4,505,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-30restructuringin_progress2012-08-012014-12-31United States (Madison, Wisconsin to San Diego, California)Diagnostics — legacy molecular diagnostics operationsUSD 6 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Total estimated severance and benefits charge of $6.1M recognized ratably over affected employees' service periods; $1.0M and $2.0M recorded in the three and six months ended March 30, 2013. No employee count disclosed.
2013-03-30othercompletedUnited States (San Diego, California)Diagnostics — Gen-Probe executive leadershipUSD 10 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Separation of certain Gen-Probe executives including former Chairman/CEO Carl Hull during Q2 FY2013, triggering acceleration of retention payments and equity awards; charge recorded in Q2 FY2013. No employee count disclosed.
2013-03-30plant_closurein_progress2012-09-292014-06-30United States (Indianapolis, Indiana to Costa Rica)Breast Health — interventional breast products manufacturingUSD 6 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		All employees at the Indianapolis location to be terminated as production transfers; $1.5M and $3.0M severance recorded in the three and six months ended March 30, 2013, plus $0.7M miscellaneous charges in Q1 FY2013. No employee count disclosed.
2013-03-30restructuringin_progress2012-06-302013-09-28Germany (Hitec-Imaging subsidiary) to United States (Newark, Delaware)Breast Health — Selenium panel coating productionUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Termination communications began January 2013; $0.6M severance recorded in Q2 FY2013; approximately $1.0M total severance expected in fiscal 2013. Primarily manufacturing personnel; no employee count disclosed.
2013-03-30divestiture_reductioncompleted2013-01-032013-03-22United StatesDiagnostics — LIFECODES business (transplant diagnostics, specialty coagulation, transfusion medicine)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of LIFECODES to Immucor, Inc. for $85.0M plus up to $10.0M contingent; closed March 22, 2013 with a $0.9M gain. No headcount associated with the divested business was disclosed.
2013-03-30acquisition_additioncompleted2012-12-312012-12-31ChinaBreast Health — distribution (Chindex Medical Limited)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of certain assets of a Breast Health distributor in China for a net purchase price of $4.5M including contingent consideration; no headcount added was disclosed.
2013-03-30restructuringin_progress2012-10-012014-12-31Madison, WisconsinDiagnosticsUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Transfer of legacy molecular diagnostics operations to San Diego. Majority of employees to be terminated in fiscal 2013 and 2014. $1.0M recorded in Q2 2013.
2013-03-30restructuringin_progress2012-10-012014-06-30Indianapolis, IndianaBreast HealthUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Transfer of interventional breast products production to Costa Rica. All employees at Indianapolis location to be terminated. $1.5M recorded in Q2 2013.
2013-03-30restructuringin_progress2012-07-012013-09-28GermanyBreast HealthUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Consolidation of Selenium panel coating production to Newark, Delaware. Terminating certain manufacturing personnel. $0.6M recorded in Q2 2013.
2013-03-30restructuringin_progress2012-10-01GlobalDiagnosticsUSD 10 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Consolidation of Diagnostics operations. Includes acceleration of retention payments and equity awards for certain Gen-Probe executives ceasing employment in Q2 2013.
2013-03-30restructuringin_progressUSD 16,395,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-30restructuringin_progressNon Guarantor Subsidiaries [Member]USD 3,518,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-30restructuringin_progressGuarantor Subsidiaries [Member]USD 13,886,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-30restructuringin_progressConsolidation Eliminations [Member]USD -1,394,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-30restructuringin_progressParent Company [Member]USD 385,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-12-29restructuringin_progress2012-06-302014-12-31Madison, Wisconsin to San Diego, CaliforniaDiagnosticsUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Fiscal 2013 Q1 charge of $1.792M for workforce reductions; includes $0.2M stock-based compensation. Total estimated severance and benefits charge approximately $6.4M, recorded ratably over service periods. Transfer of legacy molecular diagnostics operations from Madison to San Diego expected to finalize by end of calendar 2014; majority of Madison employees to be terminated in fiscal 2013 and 2014. No employee count disclosed.
2012-12-29plant_closurein_progress2012-06-302014-06-30Indianapolis, Indiana to Costa RicaBreast HealthUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Fiscal 2013 Q1 charge of $2.141M for workforce reductions. Transfer of interventional breast product production expected to complete in first half of calendar 2014; all employees at Indianapolis location will be terminated. Total estimated severance and benefits charge approximately $6.4M. No employee count disclosed.
2012-12-29restructuringannounced2013-01-012013-09-30Newark, Delaware (from Hitec-Imaging Germany)Breast HealthUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		No charges recorded as of December 29, 2012 because severance communications had not been made. Termination communications began January 2013. Expected severance charges of $1.2M to $1.4M in fiscal 2013; midpoint shown. Transfer expected to complete in second half of fiscal 2013. No employee count disclosed.
2012-12-29otherannounced2013-01-222013-08-15United StatesDiagnosticsUSD 7 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Carl Hull retiring as SVP and GM of Diagnostics; will consult through mid-August 2013. Charge of approximately $6.5M expected in fiscal 2013 Q2 for acceleration of retention payments and equity awards.
2012-12-29acquisition_additioncompleted2012-04-302012-08-01San Diego, CaliforniaDiagnosticsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Gen-Probe completed August 1, 2012 for $3.97 billion. No headcount added disclosed. Related restructuring actions captured separately above.
2012-12-29divestiture_reductionannounced2013-01-032013-03-31United StatesDiagnosticsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to sell LIFECODES business for $85.0M cash plus up to $10.0M contingent payments. Expected to close in first half of fiscal 2013. No headcount reduction disclosed.
2012-12-29restructuringin_progress2012-10-012014-12-31Madison, WisconsinDiagnosticsUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Consolidation of Diagnostics operations; transfer of legacy molecular diagnostics from Madison to San Diego. Majority of employees to be terminated in fiscal 2013 and 2014.
2012-12-29restructuringin_progress2012-10-012014-06-30Indianapolis, IndianaBreast HealthUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Closure of Indianapolis facility; transfer of interventional breast products production to Costa Rica. All employees at Indianapolis location to be terminated.
2012-12-29restructuringannounced2013-01-012013-09-28GermanyBreast Healthrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Consolidation of Selenium panel coating production from Hitec-Imaging German subsidiary to Newark, Delaware. Termination communications began in January 2013.
2012-12-29otherannounced12013-01-222013-08-15DiagnosticsUSD 7 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Retirement of Carl Hull, Senior Vice President and General Manager of Diagnostics. Charge related to acceleration of retention payments and equity awards.
2012-12-29restructuringin_progressUSD 3,933,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-12-29restructuringin_progressNon Guarantor Subsidiaries [Member]USD 426,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-12-29restructuringin_progressGuarantor Subsidiaries [Member]USD 3,286,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-12-29restructuringin_progressParent Company [Member]USD 221,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-29acquisition_additioncompleted2012-04-292012-08-01United States (San Diego, California)Diagnosticsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Merger agreement dated April 29, 2012; acquisition closed August 1, 2012 for approximately $3.97 billion. Gen-Probe headcount added is not quantified in the filing.
2012-09-29restructuringcompleted2012-04-302012-09-29Costa Rica (primarily)GYN SurgicalUSD 20 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Product line discontinued as not financially viable; $19.1M recorded in cost of product sales and $0.4M in restructuring. All identified employees terminated and paid as of fiscal year end; affected headcount not disclosed.
2012-09-29restructuringin_progress2012-08-012014-12-31United States (San Diego, California; Madison, Wisconsin)DiagnosticsUSD 15 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2012 charges comprise $13.3M severance and benefits for terminated Gen-Probe and legacy diagnostics staff (including $3.5M stock compensation) plus $1.5M for the planned Madison-to-San Diego transfer (total program estimated at $6.4M). An additional $1.1M severance expected in fiscal 2013; transfer to be finalized by end of calendar 2014. Affected headcount not disclosed.
2012-09-29plant_closurein_progress2012-06-242014-06-30United States (Indianapolis, Indiana)Breast HealthUSD 2 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Decision finalized in Q4 fiscal 2012; interventional breast product production transferring to Costa Rica, expected complete in first half of calendar 2014 with all employees at the site terminated. Total severance and benefits estimated at approximately $7.0M, recorded ratably over affected employees' service periods. Affected headcount not disclosed.
2012-09-29plant_closurein_progress2012-03-242013-09-30Germany to United States (Newark, Delaware)Breast Healthrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Decision finalized in Q3 fiscal 2012; production line moving from the Hitec-Imaging German subsidiary to Newark, Delaware, expected complete in second half of fiscal 2013. Severance expected to be $1.2M to $1.4M; no charge recorded as of September 29, 2012 because amounts were still being negotiated with the works council. Affected headcount not disclosed.
2012-09-29restructuringcompleted2011-12-262012-09-29United StatesCorporate / other operating cost reductionsUSD 0 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2012 charges of $0.47M comprising $0.4M for abandoned lease space and leasehold write-offs plus $0.1M severance for terminated employees, net of a reversal of fiscal 2011 severance accruals. Affected headcount not disclosed.
2012-09-29restructuringin_progress2012-04-30Costa RicaGYN SurgicalUSD 20 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Abandonment of Adiana product line. Terminated certain manufacturing and other personnel primarily at Costa Rica location. Aggregate charge of $19.5 million.
2012-09-29restructuringin_progress2012-08-012014-12-31United StatesDiagnosticsUSD 15 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Consolidation of Diagnostics operations following Gen-Probe acquisition. Terminated employees in R&D, sales, marketing, and G&A. Includes transfer of Madison, WI operations to San Diego, CA.
2012-09-29restructuringin_progress2012-10-012014-06-30United StatesBreast HealthUSD 2 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Closure of Indianapolis facility. Transfer of interventional breast products production to Costa Rica. All employees at location to be terminated.
2012-09-29restructuringannounced2012-07-012013-09-30GermanyBreast Healthrestructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Consolidation of Selenium panel coating production from Hitec-Imaging (Germany) to Newark, DE. Severance benefits currently being negotiated with works council; no charge recorded as of period end.
2012-09-29restructuringin_progressUSD 17,515,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-06-23restructuringcompleted2012-04-302012-06-23Costa RicaGYN Surgical — Adiana product line manufacturing and other personnelUSD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance of $138 thousand total across Q2 and Q3 FY2012; broader Adiana discontinuance totaled $19.98 million including $16.4 million non-cash impairment and $3.4 million purchase-order/contractual charges. No employee count disclosed; all identified employees terminated and paid as of 2012-06-23.
2012-06-23restructuringannounced2012-06-23Germany to United States (Newark, Delaware)Breast Health — Selenium panel coating process consolidationrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Decision finalized during Q3 FY2012; transfer expected to complete in second half of fiscal 2013. Severance benefits being negotiated with local works council; no charge recorded as of 2012-06-23 because amounts are not yet fixed or communicated. No employee count disclosed.
2012-06-23acquisition_additioncompleted2012-04-292012-08-01United States (San Diego, California)Diagnostics — Gen-Probe Incorporatedsubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Merger completed 2012-08-01 for approximately $4.0 billion, funded with cash plus $2.5 billion term loans and $1.0 billion senior notes. No headcount added disclosed; ASC 805 disclosures deferred to the fiscal 2012 Form 10-K.
2012-06-23restructuringcompleted2012-06-232012-06-23Costa RicaGYN SurgicalUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Termination of certain manufacturing and other personnel primarily at Costa Rica location related to discontinuance of Adiana system. All identified employees were terminated and paid as of June 23, 2012. Employee count not explicitly disclosed.
2012-06-23restructuringannounced2012-06-23GermanyBreast Healthrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Consolidation of Selenium panel coating process and transfer of production line from Hitec-Imaging German subsidiary to Newark, Delaware. Expected to terminate certain employees, primarily manufacturing personnel. Severance benefits currently being negotiated with local works council; no charge recorded as of June 23, 2012.
2012-06-23restructuringin_progressUSD 828,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-03-24restructuringcompleted2012-03-242012-09-30Costa RicaGYN Surgical — manufacturing and other personnelUSD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Adiana product line discontinued; terminated manufacturing and other personnel primarily at Costa Rica location. Severance $0.2M plus other contractual charges $0.2M; $3.0M accrued as of quarter-end expected paid by end of fiscal 2012. No employee count disclosed.
2012-03-24plant_closurecompleted2012-03-242012-09-30GYN Surgical — Adiana product lineUSD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Abandoned certain lease space; charges to terminate leases and write off leasehold improvements. No employee count disclosed.
2012-03-24acquisition_additioncompleted2011-06-012011-06-01ChinaDiagnostics (primarily), GYN Surgical (to a lesser extent)USD 28 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		TCT acquisition completed June 1, 2011; provides nationwide sales organization in China. Contingent earn-out payments contingent on future employment recognized as compensation expense of $27.5M for six months ended March 24, 2012. No headcount figure disclosed.
2012-03-24acquisition_additioncompleted2011-07-192011-07-19ChinaBreast HealthUSD 1 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Healthcome acquisition completed July 19, 2011; manufacturer of mammography equipment in Beijing. Future payments up to $7.1M over three years contingent on employment; compensation expense of $1.0M for six months ended March 24, 2012. No headcount figure disclosed.
2012-03-24acquisition_additionannounced2012-04-292012-12-31United StatesDiagnostics / Molecular Diagnosticssubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Merger agreement signed April 29, 2012 (after quarter-end) to acquire Gen-Probe for $82.75/share, ~$3.7B total consideration. Expected close in second half of calendar 2012. No headcount figure disclosed.
2012-03-24restructuringcompleted2012-03-242012-09-29Costa RicaGYN SurgicalUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Termination of certain manufacturing and other personnel primarily at Costa Rica location related to discontinuance of Adiana system. Employee count not disclosed.
2012-03-24acquisition_additioncompleted2011-06-01ChinaDiagnosticsbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of TCT International Co., Ltd. Headcount added not disclosed.
2012-03-24acquisition_additioncompleted2011-01-06United StatesGYN Surgicalbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Interlace Medical, Inc. Headcount added not disclosed.
2012-03-24acquisition_additioncompleted2011-07-19ChinaBreast Healthbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Beijing Healthcome Technology Company, Ltd. Headcount added not disclosed.
2012-03-24restructuringin_progressUSD 692,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-12-24restructuringcompletedUSD -91 (thousands)financial_statements
f5-10q / Qwen3.6-27B-Q8_0		Reported as 'Restructuring and divestiture (benefit) charges, net' of $(91) thousand for the three months ended December 24, 2011. No employee count disclosed.
2011-12-24restructuringin_progressUSD -91,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-09-24restructuringcompleted2011-07-012011-09-24Not specifiedNot specifiedUSD 0 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		In the fourth quarter of fiscal 2011, certain employees were terminated with a severance and benefits charge of $0.3 million, unpaid at year-end. Headcount affected not disclosed.
2011-09-24divestiture_reductioncompleted2011-07-012011-09-24Not specifiedMinor non-core product linerestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Fourth quarter fiscal 2011 sale of a minor non-core product line for $1.1 million resulting in a net gain of $0.4 million; headcount impact not disclosed.
2011-09-24acquisition_additioncompleted2011-01-062011-01-06United States (Framingham, Massachusetts)GYN Surgicalbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Interlace Medical, developer/manufacturer of MyoSure system; headcount added not disclosed.
2011-09-24acquisition_additioncompleted2011-06-012011-06-01China (Beijing)Diagnostics (primarily), GYN Surgical (lesser extent)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of TCT, distributor of medical products in China; headcount added not disclosed.
2011-09-24acquisition_additioncompleted2011-07-192011-07-19China (Beijing)Breast Healthbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Healthcome, manufacturer of mammography equipment in China; headcount added not disclosed.
2011-09-24restructuringcompleted2011-09-242011-09-24USD 0 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Termination of employment of certain employees in Q4 fiscal 2011. Charge of $0.3 million for severance benefits.
2011-09-24acquisition_additioncompleted2011-01-062011-01-06United StatesGYN Surgicalbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Interlace Medical, Inc. on January 6, 2011. Employee count not explicitly disclosed in acquisition footnote.
2011-09-24acquisition_additioncompleted2011-06-012011-06-01ChinaDiagnosticsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of TCT International Co., Ltd. on June 1, 2011. Employee count not explicitly disclosed in acquisition footnote.
2011-09-24acquisition_additioncompleted2011-07-192011-07-19ChinaBreast Healthbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Beijing Healthcome Technology Company, Ltd. on July 19, 2011. Employee count not explicitly disclosed in acquisition footnote.
2011-09-24restructuringin_progressUSD -71,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-06-25acquisition_additioncompleted2011-01-062011-01-06United StatesGYN Surgicalbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Interlace Medical (MyoSure system) closed 2011-01-06; no employee count disclosed. Purchase price $213.4M including $86.6M contingent consideration.
2011-06-25acquisition_additioncompleted2011-06-012011-06-01ChinaDiagnostics (to a lesser extent GYN Surgical)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of TCT (Beijing-based distributor) closed 2011-06-01; no employee count disclosed. Preliminary purchase price $141.9M; earn-out payments to former shareholders treated as compensation expense ($2.1M recorded in Q3 FY2011).
2011-06-25acquisition_additioncompleted2011-07-192011-07-19ChinaBreast Healthsubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Subsequent-event acquisition completed 2011-07-19, after quarter end; no employee count disclosed. Cash purchase price $9.8M plus up to $7.1M in employment-contingent payments over three years.
2011-06-25acquisition_additioncompleted2011-06-01ChinaDiagnostics, GYN Surgicalbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of TCT International Co. Ltd. completed June 1, 2011. Headcount not disclosed.
2011-06-25acquisition_additioncompleted2011-01-06United StatesGYN Surgicalbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Interlace Medical, Inc. completed Jan 6, 2011. Headcount not disclosed.
2011-06-25acquisition_additioncompleted2011-07-19ChinaBreast Healthbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Beijing Healthcome Technology Company, Ltd. completed July 19, 2011 (subsequent event). Headcount not disclosed.
2011-03-26acquisition_additioncompleted2011-01-06United States (Framingham, Massachusetts)GYN Surgicalbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Interlace Medical, Inc. closed 2011-01-06; results included in GYN Surgical from acquisition date. No employee headcount for the acquired workforce is disclosed. Separately, $2.1M in retention payments to certain Interlace employees contingent on three and six months of service is recognized as compensation expense ($1.1M recorded in the quarter).
2011-03-26acquisition_additioncompleted2011-01-06Framingham, MassachusettsGYN SurgicalUSD 2 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Interlace Medical. $2.1 million retention bonus for certain employees contingent on service.
2011-03-26acquisition_additioncompleted2010-08-05Toronto, CanadaBreast Healthbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Sentinelle Medical. Headcount not explicitly quantified.
2011-03-26plant_closurecompletedShanghai, ChinaManufacturingUSD 0 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Closure of organic photoconductor drum coatings manufacturing operation. Charge relates to prior period closure costs.
2010-12-25acquisition_additioncompleted2010-08-052010-08-05Toronto, CanadaBreast Healthbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Sentinelle Medical completed August 5, 2010; no employee headcount disclosed.
2010-12-25acquisition_additioncompleted2011-01-062011-01-06Framingham, Massachusetts, United StatesGYN Surgicalsubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Interlace Medical closed January 6, 2011 (after quarter end); no employee headcount disclosed.
2010-12-25restructuringin_progressBreast HealthUSD 0 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring charge of $51 thousand for retention accruals for certain Sentinelle Medical employees; no employee count disclosed.
2010-12-25restructuringcompletedSentinelle MedicalUSD 51 (thousands)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Ongoing retention accruals for certain employees of Sentinelle Medical.
2010-12-25acquisition_additionannounced2011-01-06GYN Surgicalsubsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Interlace Medical, Inc. consummated Jan 6, 2011. Results included beginning Q2 FY2011.
2010-12-25acquisition_additionannounced2011-01-14subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Definitive agreement signed to acquire medical equipment manufacturer. Closing subject to regulatory approval.
2010-09-25acquisition_additioncompleted2010-07-062010-08-05CanadaBreast Healthbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Sentinelle Medical completed August 5, 2010; headcount added not disclosed.
2010-09-25plant_closurecompleted2009-09-26ChinaBreast HealthUSD 1 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Shanghai organic photoconductor drum coating facility closed in Q4 FY2009; FY2010 activity includes $0.5M clean-up/closure costs and Q2 FY2010 sale of the operation for $3.8M with $0.3M loss. Severance of $0.4M and other costs of $0.4M were recorded in FY2009.
2010-09-25restructuringcompleted2010-09-25CanadaBreast HealthUSD 1 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Terminations of certain employees in connection with completing the Sentinelle Medical acquisition; severance and related benefits of $0.9M recorded in Q4 FY2010; some employees also receive stay bonuses.
2010-09-25restructuringcompleted2010-06-262010-09-25CanadaBreast HealthUSD 1 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Termination of certain employees in connection with completing the Sentinelle Medical acquisition. Terminations occurred prior to September 25, 2010.
2010-09-25plant_closurecompleted2009-12-262010-06-26ChinaBreast HealthUSD 0 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Sale of capital stock of organic photoconductor drum coating manufacturing operation in Shanghai. Closure initiated in Q4 2009 due to government requirements. Sale completed in Q2 2010 resulting in loss on disposal.
2010-06-26plant_closurecompleted2010-03-27Shanghai, ChinaManufacturing — organic photoconductor drum coatings (AEG)USD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Facility closed in Q4 FY2009 with $0.4M severance (prior fiscal year); $0.5M of FY2010 clean-up and closure costs, including stay bonuses, recorded in Q1 FY2010. Capital stock of the operation sold in Q2 FY2010 for $3.8M net, resulting in a $0.3M loss on divestiture. Number of employees affected not disclosed.
2010-06-26acquisition_additionannounced2010-07-062010-08-05Toronto, CanadaBreast HealthUSD 85 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Sentinelle Medical Inc. for $85M cash plus a two-year contingent earn-out of up to $250M; expected to close on or about August 5, 2010 subject to customary conditions including Canadian judicial approval. Headcount added not disclosed.
2010-06-26plant_closurecompleted2010-06-26Shanghai, ChinaManufacturingUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Sale of capital stock of organic photoconductor drum coating manufacturing operation completed in Q2 FY2010. Resulted in $0.3 million loss on divestiture. Prior Q4 FY2009 restructuring included $0.4 million severance for employees at this facility.
2010-06-26acquisition_additionannounced2010-07-062010-08-05Toronto, CanadaBreast HealthUSD 85 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Agreement to acquire Sentinelle Medical Inc. for $85 million cash plus up to $250 million contingent earn-out. Expected to close August 5, 2010.
2010-06-26restructuringin_progressUSD 355,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2010-03-27plant_closurecompleted2009-09-262010-03-27Shanghai, ChinaAEG organic photoconductor drum coatings manufacturingUSD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Facility closure announced in Q4 FY2009; sale of capital stock completed in Q2 FY2010 for net price of $3.8M resulting in a $0.3M loss on divestiture. Severance of $0.4M and other costs of $0.4M were recorded in FY2009; no employee count disclosed. A net credit of $0.1M from reversal of accrued amounts was recorded in Q2 FY2010.
2010-03-27othercompleted2010-02-172010-02-17United StatesBreast Health — Suros biopsy (ATEC, Eviva)USD 13 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Settlement of Ethicon patent litigation; one-time payment of $12.5M plus ongoing royalties on ATEC and Eviva hand pieces, with reciprocal royalties to Hologic on Mammotome MRI. No headcount impact disclosed; captured as a material labor/commercial event only — no employees_affected_count available.
2010-03-27plant_closurecompletedShanghai, ChinaBreast HealthUSD 487 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Closure of manufacturing facility producing organic photoconductor drum coatings. Q2 2010 incurred $487k in clean-up/closure costs. Sale of capital stock completed in Q2 2010.
2010-03-27divestiture_reductioncompletedShanghai, ChinaBreast HealthUSD -341 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Sale of capital stock of Shanghai manufacturing operation resulted in a loss on divestiture of $341k.
2010-03-27restructuringin_progressUSD 355,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2009-12-26plant_closurein_progressShanghai, ChinaAEG organic photoconductor drum coatings manufacturingUSD 487 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Facility closed in Q4 FY2009 due to Chinese government requirements to relocate; Q1 FY2010 recorded $487 clean-up and closure costs including stay bonuses, with $540 accrued at quarter-end. Severance of $420 and other costs of $377 were recorded and paid in Q4 FY2009. Number of employees affected not disclosed.
2009-12-26plant_closurein_progress2009-09-26Shanghai, ChinaManufacturingUSD 487 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Closure of manufacturing facility for organic photoconductor drum coatings. Q1 2010 charges of $487k relate to clean-up and closure costs including stay bonuses. Prior Q4 2009 charges included severance.
2009-12-26restructuringin_progressUSD 487,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2009-09-26plant_closurecompletedChina (Shanghai)Breast Health — manufacturing (organic photoconductor drum coatings)USD 1 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Closed in Q4 FY2009 due to Chinese government requirements to relocate the facility; majority of employees terminated with benefits paid by 2009-09-26, but no headcount disclosed. Charge comprises $420K severance benefits and $377K other costs; a further $1.9M of equipment impairment, accelerated depreciation and inventory write-off was recorded in cost of product sales. Additional closure costs expected in fiscal 2010, not expected to be material.
2009-09-26plant_closurecompleted2009-09-262009-09-26ChinaManufacturingUSD 1 (millions)Item 1. Business - Employees
f5-10k / Qwen3.6-27B-Q8_0		Closure of manufacturing facility in Shanghai. Majority of employees terminated; termination benefits paid as of Sept 26, 2009. Charge of $0.8 million for severance and other costs.
2009-09-26restructuringin_progressUSD 797,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2009-06-27restructuringcompleted2008-05-202009-09-26ExecutiveUSD 6,383 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Separation agreement with former Chairman Patrick J. Sullivan. Includes lump sum payment and stock-based compensation charge. Anticipated to be paid in full during fiscal 2009.
2009-06-27restructuringin_progress2007-10-222009-09-26Cytyc MergerUSD 4,658 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Liabilities related to restructuring plans approved by previous management of Cytyc to reduce future operating expenses. Includes termination benefits and other contractual obligations. Anticipated to be paid in full during fiscal 2009.
2009-06-27restructuringin_progress2008-07-242009-09-26Third Wave AcquisitionUSD 7,509 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Liabilities related to restructuring plans approved by previous management of Third Wave to reduce future operating expenses. Anticipated to be paid in full during fiscal 2009.
2009-06-27restructuringin_progressUSD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2009-03-28restructuringin_progress2009-09-26restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Legacy restructuring plans approved by prior management of Cytyc and Third Wave; accrual balances of $4,658 and $7,509 respectively at inception, no additional costs incurred this period, expected paid in full during fiscal 2009. Employee counts not disclosed.
2009-03-28restructuringin_progressCompany-wideMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cost reduction initiatives implemented in the first half of fiscal 2009 reduced headcount, bonus and other expenses; no employee counts or charges quantified.
2009-03-28restructuringin_progress2009-09-26USD 536 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Remaining balance of restructuring accruals from Cytyc and Third Wave acquisitions. Expected to be paid in full during fiscal 2009. Includes termination benefits and other costs.
2008-12-27restructuringin_progress2009-09-26USD 1,592 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Liabilities related to restructuring plans from Cytyc merger and Third Wave acquisition. Includes termination benefits and other costs. Expected to be paid in full during fiscal 2009.
2008-09-27acquisition_additioncompleted2007-10-222007-10-22United StatesDiagnostics; GYN Surgical; Breast Healthbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Business combination with Cytyc Corporation closed October 22, 2007; acquired headcount is not quantified in the filing.
2008-09-27acquisition_additioncompleted2008-07-242008-07-24United StatesDiagnosticsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Third Wave closed July 24, 2008; total acquired headcount not disclosed. Item 1 separately notes approximately 5 field service and support personnel added via this acquisition.
2008-09-27restructuringcompleted2008-05-202008-05-20United StatesCorporateUSD 6 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Compensation charge recorded on the resignation of the Executive Chairman effective May 20, 2008; includes $1.9 million of stock-based compensation. No employee count disclosed.
2008-09-27restructuringin_progress2007-10-22United States (Mountain View, California; Costa Rica; Massachusetts)CorporateUSD 5 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Termination-benefit liability assumed in the Cytyc merger for consolidation of Mountain View operations and prior Cytyc acquisitions; no additional retention costs incurred during fiscal 2008.
2008-09-27restructuringin_progress2008-07-242009-09-26United StatesDiagnosticsUSD 8 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Termination-benefit liability assumed in the Third Wave acquisition; filer expects costs paid in full during fiscal 2009. No employee count disclosed.
2008-09-27otherannounced2008-12-272008-12-31United StatesBreast Healthother
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Customers notified in the first quarter of fiscal 2009 that the GliaSite product is being discontinued; systems to be sold until inventory exhausted by end of December 2008. No workforce impact quantified.
2008-09-27restructuringcompleted2008-05-20USD 6 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Recorded $6.4 million in compensation charges related to the resignation of Executive Chairman, effective May 20, 2008.
2008-09-27acquisition_additioncompleted2008-07-24Madison, WisconsinDiagnosticsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Third Wave Technologies, Inc. completed July 24, 2008. Headcount not explicitly disclosed in acquisition footnote, but included in total employee count.
2008-09-27acquisition_additioncompleted2007-10-22Marlborough, MassachusettsDiagnostics, GYN Surgicalbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Merger with Cytyc Corporation completed October 22, 2007. Headcount not explicitly disclosed in acquisition footnote, but included in total employee count.
2008-06-28restructuringcompleted2008-05-20United StatesCorporateUSD 6,383 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Separation and Release Agreement with Chairman Patrick J. Sullivan; charge includes $1,941 stock-based compensation and a $4,442 lump sum payment. No employee count disclosed.
2008-06-28restructuringin_progress2007-10-22United StatesMultiple (Cytyc legacy operations)USD 2,800 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		EITF 95-3 liability recorded at Cytyc acquisition for termination of certain employees, minimum inventory purchase commitments, and other contractual obligations. No employee count disclosed; plan expected to be finalized within one year of acquisition.
2008-06-28restructuringin_progress2007-10-22United StatesMultiple (Cytyc legacy operations)USD 4,658 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring liability assumed from Cytyc covering consolidation of Mountain View, CA operations into Costa Rica and Massachusetts, plus Adeza and Adiana acquisitions. No employee count disclosed.
2008-06-28acquisition_additioncompleted2007-10-222007-10-22United StatesDiagnostics; GYN Surgical; Breast Healthbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Merger completed October 22, 2007; results included from that date. No headcount added disclosed.
2008-06-28acquisition_additioncompleted2007-09-182007-09-18United StatesBreast Healthbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition completed September 18, 2007 (fiscal 2007 Q4). No headcount added disclosed.
2008-06-28acquisition_additionannounced2008-07-242008-07-24United StatesDiagnosticssubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Third Wave Technologies completed July 24, 2008, after quarter end; purchase price approximately $580 million. No headcount added disclosed.
2008-06-28restructuringcompleted2008-05-20ExecutiveUSD 6 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Separation and Release Agreement with Patrick J. Sullivan, Chairman. Includes $4.4M cash payment, COBRA coverage, and $1.9M stock-based compensation charge for accelerated vesting.
2008-06-28restructuringin_progress2007-10-22GlobalVariousUSD 3 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Liability recorded in accordance with EITF 95-3 related to termination of certain employees, minimum inventory purchase commitments, and other contractual obligations for discontinued business activities.
2008-03-29acquisition_additioncompleted2007-05-202007-10-22United StatesDiagnostics; GYN Surgical; Breast Healthbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Merger completed 2007-10-22; no employee headcount added disclosed.
2008-03-29restructuringin_progress2007-10-222008-10-22United States (Mountain View, CA; Costa Rica; Massachusetts)Corporate / OperationsUSD 4,658 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring plans assumed from Cytyc merger; includes consolidation of Mountain View, CA operations into Costa Rica and Massachusetts, plus Adeza and Adiana acquisitions. No employee count disclosed. Additional EITF 95-3 liability of $2,800 thousand recorded for employee terminations and discontinued activities.
2008-03-29acquisition_additioncompleted2007-06-202007-09-18United States (Aliso Viejo, CA)Breast Healthbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition completed 2007-09-18; no employee headcount added disclosed.
2008-03-29restructuringin_progress2007-10-22Mountain View, California; Costa Rica; MassachusettsCorporate / OperationsUSD 2,800 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Company assumed Cytyc restructuring plans to consolidate Mountain View operations into Costa Rica and Massachusetts. Recorded $2.8M liability for termination benefits and contractual obligations. Employee count not disclosed.
2008-03-29acquisition_additioncompleted2007-10-22GlobalDiagnostics; GYN Surgical; Breast Healthbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Cytyc Corporation completed. Headcount added not explicitly quantified in filing.
2008-03-29acquisition_additioncompleted2007-09-18Aliso Viejo, CaliforniaBreast Healthbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of BioLucent completed. Headcount added not explicitly quantified in filing.
2007-12-29acquisition_additioncompleted2007-05-202007-10-22United StatesDiagnostics; GYN Surgicalbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Merger completed 2007-10-22; Cytyc became a wholly-owned subsidiary. No employee headcount added disclosed.
2007-12-29restructuringin_progress2007-10-222008-10-22United States (Mountain View, California; Costa Rica; Massachusetts)Corporate / operationsUSD 5 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Assumed Cytyc-approved restructuring plans consolidating Mountain View operations into Costa Rica and Massachusetts, plus Adeza/Adiana plans; liability of $4,722 thousand assumed at acquisition. No employee count disclosed; payments of $1,542 thousand made in quarter.
2007-12-29restructuringin_progress2007-10-222008-10-22United StatesCorporate / operationsUSD 3 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Liability recorded for employee terminations, minimum inventory purchase commitments and other contractual obligations for discontinued activities; $342 thousand paid for employee terminations through quarter end. No employee count disclosed.
2007-12-29acquisition_additioncompleted2007-06-202007-09-18United States (Aliso Viejo, California)Breast Healthbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition completed 2007-09-18 (MammoPad business only; brachytherapy business spun off prior to close). No employee headcount added disclosed.
2007-12-29restructuringin_progress2007-10-22GlobalVariousUSD 3 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Liability recorded in accordance with EITF 95-3 primarily related to termination of certain employees, minimum inventory purchase commitments and other contractual obligations for which business activities have been discontinued.
2007-12-29restructuringin_progress2007-10-22GlobalVariousUSD 5 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Assumed previous Cytyc management approved restructuring plans designed to reduce future operating expenses by consolidating Mountain View operations into Costa Rica and Massachusetts, and relating to Adeza and Adiana acquisitions.
2007-09-29reduction_in_forcecompleted2United StatesSuros Surgical Systems — executive management (Indianapolis, Indiana)USD 550 (thousands)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Approved in the second quarter of fiscal 2007; approximately $550 thousand severance liability recorded under EITF 95-3, of which approximately $400 thousand was paid during fiscal 2007 with the balance expected to be paid by the end of the second quarter of fiscal 2008. Announcement date not disclosed.
2007-09-29acquisition_additioncompleted4502007-05-202007-10-22Sales forceItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Merger agreement dated 2007-05-20; business combination consummated 2007-10-22 (subsequent to fiscal year-end). Count is approximate and reported as of 2007-11-12.
2007-09-29acquisition_additioncompleted1752007-05-202007-10-22Field service engineers, internal technical support and related administrative personnelItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Merger agreement dated 2007-05-20; business combination consummated 2007-10-22 (subsequent to fiscal year-end). Count is approximate and reported as of 2007-11-12.
2007-09-29acquisition_additioncompleted2007-06-202007-09-18United StatesMammography/Breast Care — MammoPad businessbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement dated 2007-06-20, acquisition completed 2007-09-18. Only the MammoPad cushion business was acquired after BioLucent spun off its brachytherapy unit; headcount acquired not disclosed.
2007-09-29restructuringcompleted532006-12-312007-09-29GermanyManufacturing and administrativerestructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Termination of 53 manufacturing and administrative personnel of acquired AEG Elektrofotografie subsidiaries in Germany.
2007-09-29restructuringcompleted212006-12-312007-09-29United StatesManufacturing and administrativerestructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Termination of 21 manufacturing and administrative personnel of acquired AEG Elektrofotografie subsidiaries in the United States.
2007-09-29restructuringcompleted582006-12-312007-09-29United StatesAll functional areasrestructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Termination of 58 personnel of acquired R2 Technology across all functional areas.
2007-09-29restructuringcompleted22007-06-302007-09-29United StatesExecutive managementrestructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Termination of two members of the Suros executive management team.
2007-09-29acquisition_additioncompleted4502007-10-222007-10-22GlobalSales forceItem_1_Business
f5-10k / Qwen3.6-27B-Q8_0		Addition of approximately 450 people to sales force as a result of business combination with Cytyc.
2007-09-29acquisition_additioncompleted1752007-10-222007-10-22GlobalField service and technical supportItem_1_Business
f5-10k / Qwen3.6-27B-Q8_0		Addition of approximately 175 people serving field service, internal technical support, and related administrative functions as a result of business combination with Cytyc.
2007-06-30restructuringcompleted53GermanyOther (AEG photoconductor materials) — manufacturing and administrativerestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Headcount reduction plan approved in Q4 fiscal 2006; plan completed during the three months ended June 30, 2007, at which point the remaining ~$369 thousand accrual (not split by geography) was reversed against goodwill. Original AEG severance liability was ~$2,400 thousand total for both geographies.
2007-06-30restructuringcompleted21United StatesOther (AEG photoconductor materials) — manufacturing and administrativerestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Headcount reduction plan approved in Q4 fiscal 2006; plan completed during the three months ended June 30, 2007, at which point the remaining ~$369 thousand accrual (not split by geography) was reversed against goodwill. Original AEG severance liability was ~$2,400 thousand total for both geographies.
2007-06-30restructuringcompleted2United StatesMammography/Breast Care (Suros Surgical Systems) — executive managementUSD 550 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan finalized and approved during the nine months ended June 30, 2007; two members of the Suros executive team terminated. ~$381 thousand of the severance liability paid in the period, balance expected to be paid by the end of fiscal Q2 2008.
2007-06-30restructuringcompleted532006-10-012007-06-30GermanyManufacturing and AdministrativeUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Part of AEG acquisition restructuring plan finalized in Q4 FY2006. Completed in Q3 FY2007 with remaining accrual reduced to zero.
2007-06-30restructuringcompleted212006-10-012007-06-30United StatesManufacturing and AdministrativeUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Part of AEG acquisition restructuring plan finalized in Q4 FY2006. Completed in Q3 FY2007 with remaining accrual reduced to zero.
2007-06-30restructuringin_progress582006-10-01United StatesAll functional areasUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Part of R2 acquisition restructuring plan finalized in Q4 FY2006. Plan finalized, no additional amounts recorded.
2007-06-30restructuringin_progress22007-01-012008-03-31United StatesExecutive ManagementUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Part of Suros acquisition restructuring plan finalized in Q1 FY2007. Terminated two members of executive management team.
2007-03-31restructuringcompleted532006-09-30GermanyManufacturing and administrativerestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan approved in fiscal Q4 2006; exact announcement date not disclosed. Part of a consolidated severance liability of approximately $3,435 thousand across all reduction plans, with $2,669 thousand paid through 2007-03-31 and $766 thousand remaining, expected to be paid through the first six months of fiscal 2008
2007-03-31restructuringcompleted212006-09-30United StatesManufacturing and administrativerestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		AEG acquired subsidiaries headcount reduction approved in fiscal Q4 2006; exact announcement date not disclosed. Severance liability recorded under EITF 95-3 was approximately $2,400 thousand for the AEG plan, of which about $1,868 thousand had been paid as of 2007-03-31
2007-03-31restructuringcompleted582006-09-30United StatesR2 Technology — all functional areasrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan approved in fiscal Q4 2006 covering personnel across all functional areas of R2; exact announcement date not disclosed. Related EITF 95-3 liability of approximately $798 thousand (including lease abandonment), of which about $585 thousand paid as of 2007-03-31
2007-03-31restructuringcompleted22007-03-31United StatesSuros Surgical Systems — executive managementUSD 550 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan finalized and approved during the three months ended 2007-03-31; exact announcement date within the quarter not disclosed. Two members of the Suros executive management team terminated; approximately $335 thousand of the $550 thousand liability paid during the quarter, balance expected to be paid by the end of the second quarter of fiscal 2008
2007-03-31restructuringin_progress532006-10-01GermanyManufacturing and Administrativerestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Part of AEG acquisition restructuring plan finalized in Q4 FY2006.
2007-03-31restructuringin_progress212006-10-01United StatesManufacturing and Administrativerestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Part of AEG acquisition restructuring plan finalized in Q4 FY2006.
2007-03-31restructuringin_progress582006-10-01United StatesAll functional areasrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Part of R2 acquisition restructuring plan finalized in Q4 FY2006.
2007-03-31restructuringcompleted22007-03-31United StatesExecutive Managementrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Part of Suros acquisition restructuring plan finalized in Q2 FY2007.
2006-12-30restructuringin_progress532007-09-29GermanyManufacturing and administrative (AEG subsidiaries)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Headcount reduction plan approved in fiscal Q4 2006 (announcement date not stated in this filing). Severance liability of $2,886 thousand covers all three sub-components combined; not allocated by component. $1,925 thousand paid through 2006-12-30; remaining $961 thousand expected to be paid in fiscal 2007.
2006-12-30restructuringin_progress212007-09-29United StatesManufacturing and administrative (AEG subsidiaries)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Same AEG headcount reduction plan as the Germany component; plan approved in fiscal Q4 2006. Severance liability disclosed only in aggregate ($2,886 thousand across all components); $1,925 thousand paid through 2006-12-30.
2006-12-30restructuringin_progress582007-09-29United StatesAll functional areas (R2 Technology)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan approved in fiscal Q4 2006 covering terminations across all functions of acquired entity R2 (Santa Clara, California). Related acquisition-date liability of $798 thousand also included $312 thousand lease-abandonment costs; $372 thousand paid through 2006-12-30. Severance portion not separately disclosed.
2006-12-30restructuringin_progress532006-10-012007-09-29GermanyManufacturing and Administrativerestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Part of AEG acquisition restructuring plan finalized in Q4 FY2006. Total liability for AEG was $2,400k; $1,600k paid as of Dec 30, 2006.
2006-12-30restructuringin_progress212006-10-012007-09-29United StatesManufacturing and Administrativerestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Part of AEG acquisition restructuring plan finalized in Q4 FY2006. Total liability for AEG was $2,400k; $1,600k paid as of Dec 30, 2006.
2006-12-30restructuringin_progress582006-10-012007-09-29United StatesAll functional areasrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Part of R2 acquisition restructuring plan finalized in Q4 FY2006. Total liability for R2 was $798k; $372k paid as of Dec 30, 2006.
2006-09-30reduction_in_forcecompleted532006-05-022006-09-30GermanyAEG Elektrofotografie subsidiaries — manufacturing and administrativerestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Plan finalized in Q4 fiscal 2006; announcement date set to AEG acquisition date when the plan was first formulated. AEG program severance liability was approximately $2.1 million (EITF 95-3), not allocated between the Germany and U.S. components; total severance across the AEG and R2 plans was $2,584 thousand with $1,048 thousand paid through 2006-09-30.
2006-09-30reduction_in_forcecompleted212006-05-022006-09-30United StatesAEG Elektrofotografie subsidiaries — manufacturing and administrativerestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Same AEG headcount reduction plan as the Germany component; charge not allocated between sub-components.
2006-09-30reduction_in_forcecompleted582006-07-132006-09-30United StatesR2 Technology, Inc. — all functional areasrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Plan finalized in Q4 fiscal 2006; announcement date set to R2 acquisition date. R2 program liability was approximately $798 thousand, including $312 thousand of lease abandonment costs for Santa Clara, California space; severance portion not separately stated.
2006-09-30acquisition_additioncompleted2006-05-022006-05-02Germany, China, United StatesOther segment — photoconductor coatingsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Headcount added not disclosed; Item 1 separately references approximately 200 non-management German employees and 85 non-management employees of AEG's Chinese subsidiary.
2006-09-30acquisition_additioncompleted2006-07-132006-07-13United StatesMammography/Breast Care — computer-aided detection (CAD)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Headcount added not disclosed; 58 positions were subsequently eliminated under the R2 reduction plan.
2006-09-30acquisition_additioncompleted2006-07-272006-07-27United StatesMammography/Breast Care — breast biopsy devicesbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Headcount added not disclosed; Item 1 notes the Suros sales force was included in the direct sales and service force as of 2006-11-17.
2006-09-30restructuringcompleted532006-05-022006-12-31GermanyManufacturing and administrativeUSD 2 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Termination of 53 manufacturing and administrative personnel of acquired AEG subsidiaries in Germany. Liability of approx $2.1M recorded.
2006-09-30restructuringcompleted212006-05-022006-12-31United StatesManufacturing and administrativerestructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Termination of 21 manufacturing and administrative personnel of acquired AEG subsidiaries in the US. Included in total AEG liability.
2006-09-30restructuringcompleted582006-07-132006-12-31United StatesAll functional areasUSD 1 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Termination of 58 personnel of acquired R2 Technology across all functional areas. Liability of approx $798k recorded.
2006-06-24acquisition_additioncompleted2006-05-022006-05-02Germany (operations in Germany, China and the United States)Other (photoconductor materials business)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired 100% of AEG Elektrofotografie GmbH and related companies for approximately $31.3 million; acquired headcount not disclosed.
2006-06-24restructuringin_progress2006-05-022007-05-02GermanyOther (AEG photoconductor business)USD 350 (thousands)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Liability recorded at the acquisition date for terminating certain AEG employees; no amounts paid as of June 24, 2006. Plan expected to be finalized within one year of acquisition, with any additional liabilities increasing goodwill. Number of employees affected not disclosed.
2006-06-24acquisition_additioncompleted2006-04-242006-07-13United States (Sunnyvale, California)Mammography (computer-aided detection)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Merger completed July 13, 2006 for approximately $220.0 million paid entirely in Hologic common stock; acquired headcount not disclosed.
2006-06-24acquisition_additioncompleted2006-04-172006-07-27United States (Indianapolis, Indiana)Mammography (interventional breast biopsy)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Merger completed July 27, 2006 for approximately $240 million (about $135 million cash plus 2,330 thousand shares) plus a two-year cash earn-out; acquired headcount not disclosed.
2006-06-24restructuringin_progress2006-05-02GermanyOther (AEG)USD 350 (thousands)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Liability recorded for termination of certain employees under restructuring plan; no amounts paid as of June 24, 2006.
2006-06-24acquisition_additioncompleted2006-05-02Germany, China, United StatesOther (AEG)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired AEG Elektrofotografie GmbH; headcount not explicitly disclosed.
2006-06-24acquisition_additioncompleted2006-07-13United StatesMammography (R2 Technology)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Acquired R2 Technology, Inc.; headcount not explicitly disclosed.
2006-06-24acquisition_additioncompleted2006-07-27United StatesOther (Suros Surgical)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Acquired Suros Surgical Systems, Inc.; headcount not explicitly disclosed.
2006-03-25acquisition_additioncompleted2005-09-292005-09-29United StatesMammographyUSD 4 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired Fischer Imaging mammography IP and customer lists for ~$33.0M total; $4.2M expensed as in-process R&D. No headcount disclosed.
2006-03-25acquisition_additionannounced2006-04-17United StatesMammography / Breast BiopsyUSD 240 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Suros Surgical Systems for $240M plus two-year earn-out; $132M cash at closing. No headcount disclosed.
2006-03-25acquisition_additionannounced2006-04-24United StatesMammography / CADUSD 220 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire R2 Technology for $220M payable in Hologic shares. No headcount disclosed.
2006-03-25acquisition_additioncompleted2006-05-022006-05-02GermanyMammography / Digital DetectorsEUR 21 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired AEG Elektrofotografie GmbH for EUR 21M plus EUR 1.7M earn-out; sole supplier of amorphous selenium photoconductor coatings. No headcount disclosed.
2005-09-24acquisition_additioncompleted2005-06-222005-09-29United States (Denver, Colorado)MammographyUSD 32 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Fischer Imaging Corporation mammography intellectual property for $32 million; no employee headcount transferred or disclosed. Company expects an approximately $4 million in-process R&D write-off in Q1 fiscal 2006 and approximately $2.5 million annual intangible amortization beginning fiscal 2006.
2004-09-25acquisition_additioncompleted2003-10BelgiumMammographyItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of distribution business including key service and application personnel, inventory and related assets; headcount added not quantified. Cash paid of $341 thousand shown in investing activities.
2004-09-25othercompleted2004-09-25United StatesOther (digital general radiography systems)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Product line phase-out completed during fiscal 2004; no restructuring charge recorded in fiscal 2004 and no affected-employee count disclosed
2003-09-27acquisition_additioncompleted2003-102003-10BelgiumMammography sales and serviceItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of the mammography distribution business from independent distributor VH Services NV, including key service and application personnel, inventory and related assets; occurred after the September 27, 2003 fiscal year end. Headcount added not quantified.
2003-09-27restructuringcompleted132002-06-30United States and EuropeAll functional areasUSD 495 (thousands)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Second quarter fiscal 2002 severance costs for workforce reduction.
2003-09-27plant_closurecompleted852002-03-312002-01-31Littleton, MassachusettsConventional general radiography manufacturingUSD 806 (thousands)MD&A
f5-10k / Qwen3.6-27B-Q8_0		First quarter fiscal 2002 severance costs related to termination of employees at Littleton facility. Facility closed January 2002.
2003-09-27plant_closurecompleted52002-03-31Paris, FranceDirect sales and service officeUSD 561 (thousands)MD&A
f5-10k / Qwen3.6-27B-Q8_0		First quarter fiscal 2002 severance costs for closure of Paris office.
2003-09-27restructuringcompleted202002-03-31United StatesLorad workforceUSD 208 (thousands)MD&A
f5-10k / Qwen3.6-27B-Q8_0		First quarter fiscal 2002 severance costs for continued reduction of Lorad workforce.
2003-06-28othercompleted38United StatesMammography — direct sales and field serviceMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		After terminating a U.S. independent dealer representing about half the U.S. mammography market in fiscal Q2 2003, the company hired 10 sales and 28 service personnel to cover those territories directly; targeted hires only, not total period hiring
2003-06-28restructuringcompleted132003-03-302003-03-30United States and EuropeAll functional areasUSD 495 (thousands)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Reduction of workforce by 13 persons across all functional areas in Q2 FY2003.
2003-06-28restructuringcompleted852002-12-292002-12-29United StatesLittleton facilityUSD 806 (thousands)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Termination of 85 employees at Littleton facility in Q1 FY2003.
2003-06-28restructuringcompleted52002-12-292002-12-29FranceDirect sales and service officeUSD 561 (thousands)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Closure of direct sales and service office in Paris, France in Q1 FY2003.
2003-06-28restructuringcompleted202002-12-292002-12-29United StatesLoradUSD 208 (thousands)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Continued reduction of Lorad's workforce by 20 persons in Q1 FY2003.
2003-03-29plant_closurecompleted8520012002-01Littleton, Massachusetts, United StatesHologic Systems Division — conventional general radiography manufacturingUSD 806 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Announced in the first quarter of fiscal 2002 as part of the Hologic Systems Division exit strategy; closure completed January 2002. An additional $3,500 thousand was accrued in the fourth quarter of fiscal 2001 within the Trex Medical purchase price allocation for lease abandonment and asset/receivable write-offs. Program-level restructuring liability of $51 thousand remained at 2003-03-29 after $56 thousand of cash payments during the six months then ended; no new restructuring charges were taken in the current period.
2003-03-29plant_closurecompleted52001Paris, FranceDirect sales and service officeUSD 561 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance incurred in the first quarter of fiscal 2002 for closing the direct sales and service office; specific closure date not stated.
2003-03-29restructuringcompleted202001Lorad — all functional areasUSD 208 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Continued reduction of Lorad's workforce across all functional areas; severance incurred in the first quarter of fiscal 2002. Location of affected employees not stated.
2003-03-29restructuringcompleted132002United States and EuropeAll functional areasUSD 495 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance incurred in the second quarter of fiscal 2002 (quarter ended March 30, 2002) for a workforce reduction across all functional areas; exact announcement date within the quarter not stated.
2003-03-29othercompleted10United StatesSalesMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sales personnel hired during the second quarter of fiscal 2003 after terminating an independent U.S. dealer that had represented almost half of the U.S. mammography market, as the company moved to direct sales and service coverage.
2003-03-29othercompleted28United StatesServiceMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Service personnel hired during the second quarter of fiscal 2003 to support direct coverage of territories previously assigned to distributors; MD&A warns these added service costs will pressure mammography gross profits for the remainder of fiscal 2003.
2003-03-29restructuringcompleted852002-01-012002-01-31United StatesGeneral RadiographyUSD 806 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Termination of 85 employees at Littleton facility as part of Hologic Systems Division exit strategy.
2003-03-29restructuringcompleted52002-01-012002-01-31FranceSales and ServiceUSD 561 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Closure of direct sales and service office in Paris.
2003-03-29restructuringcompleted202002-01-012002-01-31United StatesMammographyUSD 208 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Reduction of Lorad workforce across all functional areas.
2003-03-29restructuringcompleted132002-04-012002-06-30United States and EuropeAll functional areasUSD 495 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Reduction of workforce in US and Europe by 13 persons.
2002-12-28restructuringcompleted852002-01-012002-01-31Littleton, MassachusettsGeneral Radiography / Hologic Systems DivisionUSD 806 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance costs related to termination of 85 employees at Littleton facility. Closure completed in January 2002.
2002-12-28restructuringcompleted52002-01-012002-01-31Paris, FranceDirect Sales and ServiceUSD 561 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance costs in connection with closure of direct sales and service office in Paris.
2002-12-28restructuringcompleted202002-01-012002-01-31United StatesLoradUSD 208 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance costs related to continued reduction of Lorad's workforce across all functional areas.
2002-09-28plant_closurecompleted802001-11-132002-01-31United States — Littleton, MassachusettsConventional general radiography manufacturingUSD 806 (thousands)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Closure of Littleton facility acquired via Trex Medical; charge incurred in Q1 FY2002. MD&A narrative cites 85 employees while footnote and Item 1 cite 80.
2002-09-28plant_closurecompleted52001-11-132002-01-31France — ParisDirect sales and service officeUSD 561 (thousands)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Closure of direct sales and service office in Paris; charge incurred in Q1 FY2002.
2002-09-28restructuringcompleted202001-11-132002-01-31United StatesLorad (mammography)USD 208 (thousands)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Continued reduction of Lorad workforce across all functional areas; charge incurred in Q1 FY2002.
2002-09-28restructuringcompleted132001-11-132002-04-30United States and EuropeAll functional areasUSD 495 (thousands)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Additional workforce reduction across US and Europe; charge incurred in Q2 FY2002.
2002-09-28restructuringcompleted852002-01-012002-09-28United StatesGeneral RadiographyUSD 1 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Severance costs related to the termination of 85 employees at the Littleton facility in the first quarter of fiscal 2002.
2002-09-28restructuringcompleted52002-01-012002-09-28FranceSales and ServiceUSD 1 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Severance costs in connection with the closure of the direct sales and service office in Paris, France.
2002-09-28restructuringcompleted202002-01-012002-09-28United StatesMammographyUSD 0 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Severance costs related to the continued reduction of Lorad's workforce.
2002-09-28restructuringcompleted132002-04-012002-09-28United States and EuropeAll functional areasUSD 0 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Severance costs in connection with the reduction of the workforce in the second quarter of fiscal 2002.
2002-06-29plant_closurecompleted852002-01United States — Littleton, MassachusettsHologic Systems Division — conventional general radiography manufacturingUSD 806 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Exit strategy for Hologic Systems Division finalized in Q1 FY2002; closure commenced Q1 and completed January 2002. Charge primarily severance for 85 terminated employees; separate ~$3,500 accrual for lease abandonment and asset write-offs was recorded in Q4 FY2001 as part of Trex purchase price allocation.
2002-06-29plant_closurecompleted5France — ParisDirect sales and service officeUSD 561 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance in connection with closure of the Company's direct sales and service office in Paris, France; incurred in Q1 FY2002.
2002-06-29restructuringcompleted20United StatesLorad — all functional areasUSD 208 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Continued reduction of Lorad's workforce; severance incurred in Q1 FY2002 across all functional areas.
2002-06-29restructuringcompleted13United States and EuropeAll functional areasUSD 495 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Additional severance costs incurred in Q2 FY2002 for workforce reduction of 13 persons across all functional areas in the US and Europe.
2002-06-29restructuringcompleted852002-01-012002-01-31Littleton, MassachusettsHologic Systems DivisionUSD 806 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance costs related to termination of 85 employees at Littleton facility; closure completed in January 2002.
2002-06-29restructuringcompleted52002-01-012002-01-31Paris, FranceSales and ServiceUSD 561 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance costs in connection with closure of direct sales and service office in Paris.
2002-06-29restructuringcompleted202002-01-012002-01-31United StatesLoradUSD 208 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance costs related to continued reduction of Lorad's workforce.
2002-06-29restructuringcompleted132002-04-012002-06-29United States and EuropeAll functional areasUSD 495 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Additional severance costs incurred in second quarter for reduction of workforce by 13 persons.
2002-03-30plant_closurecompleted852001-10-012002-01-31United States — Littleton, MassachusettsHologic Systems Division (conventional general radiography manufacturing)USD 806 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Closure of conventional general radiography manufacturing facility announced in Q1 FY2002; closure completed January 2002. Severance charge of approximately $806 thousand in Q1 FY2002. A separate ~$3,500 thousand accrual for lease abandonment and asset write-offs was recorded in Q4 FY2001 as part of Trex Medical purchase price allocation.
2002-03-30plant_closurecompleted52001-10-012002-03-30France — ParisDirect sales and service officeUSD 561 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance costs for closure of direct sales and service office in Paris, incurred in Q1 FY2002; reductions across all functional areas.
2002-03-30restructuringcompleted202001-10-012002-03-30United StatesLorad (mammography) — continued workforce reductionUSD 208 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Continued reduction of Lorad's workforce in Q1 FY2002 across all functional areas.
2002-03-30restructuringcompleted132001-12-302002-03-30United States and EuropeAll functional areasUSD 495 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 FY2002 severance costs for workforce reduction of 13 persons across all functional areas in the US and Europe.
2002-03-30restructuringcompleted852002-01-012002-01-31United StatesGeneral RadiographyUSD 806 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Closure of Littleton manufacturing facility; completed January 2002.
2002-03-30restructuringcompleted52002-01-012002-03-30FranceSales & MarketingUSD 561 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Closure of direct sales and service office in Paris.
2002-03-30restructuringcompleted202002-01-012002-03-30United StatesBone AssessmentUSD 208 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Continued reduction of Lorad's workforce.
2002-03-30restructuringcompleted132002-02-012002-03-30United States and EuropeAll functional areasUSD 495 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Second quarter workforce reduction across US and Europe.
2001-12-29plant_closurecompleted852002-01United States — Littleton, MassachusettsHologic Systems Division — conventional general radiography manufacturingUSD 806 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Exit strategy announced during Q1 FY2002 (exact date not stated); closure commenced in the quarter and completed January 2002. Severance charge primarily for terminating 85 employees; product lines and support staff relocated to Bedford, MA HQ. A separate ~$3,500 thousand accrual for lease abandonment and asset write-offs was recorded in Q4 FY2001 as part of Trex Medical purchase price allocation.
2001-12-29plant_closurein_progress5France — ParisDirect sales and service officeUSD 561 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance costs in connection with closure of the direct sales and service office in Paris; completion timing not disclosed.
2001-12-29reduction_in_forcein_progress20United StatesLorad (mammography) — all functional areasUSD 208 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Continued reduction of Lorad's workforce across all functional areas; described as ongoing, with no completion date given.
2001-12-29restructuringcompleted852001-12-292002-01-31United StatesGeneral RadiographyUSD 806 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance costs related to termination of 85 employees at Littleton facility. Closure completed in January 2002.
2001-12-29restructuringcompleted52001-12-292001-12-29FranceSales & MarketingUSD 561 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance costs in connection with closure of direct sales and service office in Paris.
2001-12-29restructuringcompleted202001-12-292001-12-29United StatesMammographyUSD 208 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance costs related to continued reduction of Lorad's workforce.
2001-09-29restructuringin_progress8010%2001-08-13United StatesCompany-wideUSD 1 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Company-wide cost savings initiative; 10% workforce reduction. Filer expects annual cost savings exceeding $10 million once completed. Charge of approximately $1,018 thousand incurred in FY2001.
2001-09-29plant_closurecompleted2001-04-012001-04-30United StatesMini c-arm imaging (Fluoroscan)USD 1 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Fluoroscan operations relocated from Northbrook, Illinois to Bedford, Massachusetts. Total $500K expenses included $200K moving, $100K severance, $100K facility vacate, $100K other.
2001-09-29plant_closureannounced802001-11-13United StatesMammography/General Radiography (Littleton facility)USD 1 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Closure of Littleton, Massachusetts conventional X-ray manufacturing facility announced after fiscal year-end. Severance charge expected in Q1 FY2002. Additional $3.5M accrued in purchase price allocation for lease abandonment and asset write-offs. Some product lines and personnel to relocate to Bedford, MA.
2001-09-29restructuringcompleted10%2001-08-13Company-wideAll business unitsUSD 1 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Announced August 13, 2001. Planned reduction of workforce by 10%, or approximately eighty employees. Incurred $1.0 million restructuring charge primarily for severance.
2001-09-29plant_closureannounced802001-11-13Littleton, MassachusettsConventional X-ray equipment manufacturingUSD 1 (millions)Item_1_Business
f5-10k / Qwen3.6-27B-Q8_0		Announced November 13, 2001. Closure of Littleton facility. Eliminating approximately 80 employees. Expected to incur $1.0 million restructuring charge in Q1 FY2002.
2001-09-29restructuringcompleted2001-04-01Northbrook, Illinois to Bedford, MassachusettsFluoroscan mini c-arm manufacturingUSD 1 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Relocation of Fluoroscan operations in April 2001. Incurred $500,000 in expenses including $100,000 in severance costs.
2001-06-30restructuringcompleted2001-04-012001-06-30United States (Northbrook, Illinois to Bedford, Massachusetts)Mini C-Arm Imaging (Fluoroscan operations)USD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Move of Fluoroscan operations completed April 2001; charge comprised of $200K moving, $100K severance, $100K facility vacate, $100K other. Severance headcount not disclosed.
2001-06-30reduction_in_forcecompleted212001-06-012001-06-01United StatesMammography/General Radiography (Lorad facility)USD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		21 positions reduced at Lorad facility effective June 1, 2001.
2001-06-30restructuringannounced8010%2001-08-132001-09-29United StatesCompany-wideUSD 1 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Company-wide cost savings initiative announced August 13, 2001; 10% workforce reduction (~80 employees) with expected annual savings of ~$10 million. Charge primarily severance, expected in Q4 FY2001.
2001-06-30restructuringcompleted212001-06-012001-06-30United StatesMammography/General Radiography (Lorad facility)USD 200 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Reduction of 21 positions at Lorad facility; $200k severance charges incurred in current quarter.
2001-06-30restructuringannounced8010%2001-08-132001-09-29Company-wideAll business unitsUSD 1 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Announced overall restructuring plan focusing on cost savings; planned reduction of workforce by 10% (approx. 80 employees); expects $1.2M charge primarily for severance in Q4 FY2001.
2001-03-31othercompletedUnited States (Northbrook, Illinois to Bedford, Massachusetts)Fluoroscan (Mini C-Arm Imaging)USD 500 (thousands)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Completed relocation of Fluoroscan operations to corporate headquarters; approximately $500,000 of move-related expenses expected in the third quarter of fiscal 2001. No employee count disclosed.
2000-12-30acquisition_additioncompleted2000-09-15United StatesMammography/General Radiographybusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of U.S. business assets of Trex Medical Systems Corporation; no employee count disclosed.
2000-12-30otherannounced2001-06-30United States (Northbrook, Illinois to Bedford, Massachusetts)Fluoroscan mini c-arm operationsUSD 500 (thousands)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Announced relocation of Fluoroscan operations to Bedford HQ; about $500,000 of expenses expected in Q2 fiscal 2001; no employee count or headcount impact disclosed.
2000-09-30acquisition_additioncompleted2000-09-152000-09-15United StatesMammography and general radiography (Lorad division)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of substantially all U.S. business assets of Trex Medical on September 15, 2000. Headcount added not separately disclosed; $5,000 thousand allocated to in-process R&D and $3,000 thousand to assembled workforce intangible.
2000-09-30acquisition_additioncompleted1999-06-031999-06-03United StatesDirect-to-digital imaging (Direct Radiography Corp.)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition completed June 3, 1999 (prior fiscal year). Headcount added not disclosed. Included here for context as DRC operations contributed to FY2000 workforce.
2000-09-30restructuringcompleted1999-07-01United StatesCorporateMD&A
f5-10k / Qwen3.6-27B-Q8_0		In the third quarter of 1999, we reduced our U.S. workforce by approximately 10% through attrition and a corporate downsizing.
1999-09-25restructuringcompleted10%United StatesCorporateMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cost-reduction strategy in Q3 FY1999 reduced U.S. workforce by approximately 10% through attrition and corporate downsizing; savings not fully realized until Q4 FY1999
1999-09-25acquisition_additioncompleted1999-06-031999-06-03United StatesDigital Imaging (Direct Radiography Corp.)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Direct Radiography Corp. on June 3, 1999 for approximately $21.1M; specific headcount added not disclosed
1999-09-25divestiture_reductioncompleted1999-06-291999-06-29United StatesMedical Data Management divisionMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Medical Data Management division sold to Synarc, Inc. on June 29, 1999 in exchange for minority ownership; specific headcount removed not disclosed
1999-09-25restructuringcompleted1999-07-011999-09-25United StatesCorporateMD&A
f5-10k / Qwen3.6-27B-Q8_0		Reduced U.S. workforce by approximately 10% through attrition and corporate downsizing in the third quarter of fiscal 1999.
1999-06-26restructuringcompleted10%1999-06-261999-06-26United StatesCorporateMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Approximately 10% of U.S. workforce reduced via attrition and corporate downsizing in Q3 FY1999; severance expenses offset by discretionary spending savings in the same quarter. Cost savings expected fully realized in Q4 FY1999.
1999-06-26acquisition_additioncompleted1999-06-031999-06-03United StatesDirect Radiography Corporation (DRC)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of DRC completed June 3, 1999 for approximately $20 million ($7M cash, ~1.86M shares). Headcount added not disclosed. DRC contributed approximately $173,000 in revenues and approximately $1.5 million in total costs for the one month included in the period.
1999-06-26divestiture_reductioncompleted1999-06-291999-06-29United StatesMedical Data Management (MDM) divisionother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		MDM division sold to Synarc, Inc. in exchange for a minority ownership stake. No gain or loss recognized. MDM revenues were $1.2 million for first nine months of fiscal 1999. Headcount removed not disclosed.
1999-06-26restructuringcompleted10%1999-06-261999-06-26United StatesCorporateMD&A
f5-10q / Qwen3.6-27B-Q8_0		Company reduced U.S. workforce by approximately 10% through attrition and corporate downsizing. Severance expenses were offset by cost savings.
1999-06-26acquisition_additioncompleted1999-06-031999-06-03DelawareDirect Radiography Corporationbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired 100% of Direct Radiography Corporation (DRC). Headcount not explicitly disclosed.
1999-06-26divestiture_reductioncompleted1999-06-291999-06-29Medical Data Managementother
f5-10q / Qwen3.6-27B-Q8_0		Sold Medical Data Management (MDM) division to Synarc, Inc. Headcount not explicitly disclosed.
1999-03-27restructuringannounced10%1999-04-01United StatesU.S. workforceMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Approximately 10% of U.S. workforce reduced through attrition and corporate downsizing; severance expenses expected to be offset by cost savings in Q3 FY1999.
1999-03-27acquisition_additionannounced1999-04-28Delaware, United StatesDirect Radiography Corporation (digital X-ray systems)USD 30 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Purchase price approximately $30 million ($10M cash + 2.5M shares); no headcount for DRC disclosed. Company expects monthly expenditures of $1-1.5M to fund DRC operations until meaningful revenue is achieved.
1999-03-27restructuringannounced10%1999-04-01United StatesMD&A
f5-10q / Qwen3.6-27B-Q8_0		Company implemented cost-reduction strategy reducing U.S. workforce by approximately 10% through attrition and corporate downsizing.
1997-09-27acquisition_additioncompleted1996-08-291996-08-29United StatesMini C-arm Imaging (FluoroScan)USD 2 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		All-stock pooling-of-interests merger completed August 29, 1996; headcount added not disclosed. Acquisition expenses of $1.9M expensed in fiscal 1996.
1996-09-28acquisition_additioncompleted1996-08-291996-08-29United StatesMini c-arm imaging (FluoroScan)USD 2 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Pooling-of-interests merger completed August 29, 1996; 1,454,901 Hologic shares issued. Acquisition expenses of $1.9M expensed in fiscal 1996. Employee headcount added not disclosed.
1995-09-30restructuringcompleted1993-09-251994-09-24EuropeEuropean operationsUSD 1 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Fiscal 1993 restructuring charge of $900,000 related to reorganization of European operations, including workforce reduction. Completed at end of fiscal 1994.